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1. Introduction 
Subclinical hypothyroidism (sHT) is defined as serum thyrotropin-stimulating hormone 
(TSH) concentration above the statistically defined upper limit of the reference range in the 
face of serum free T4 (FT4) and free T3 (FT3) concentrations within the normal range (Ross, 
2004). sHT is a frequent condition among the general population, especially middle-aged 
and elderly women (Canaris et al., 2000). Depending on the degree of TSH elevation, sHT 
has been associated with hyperlipidemia, intermediary metabolism alterations, arterial 
hypertension and cardiovascular disease (CVD) as well as neuropsychiatric features, 
including cognitive impairment (Ashizawa et al., 2010; Biondi & Cooper., 2008; Cappola et 
al., 2006; Ceresini et al., 2010; Mitrou et al., 2011; Monzani et al., 2006; Rodondi et al., 2010; 
Tan et al., 2008; Tappy, 1987). Interestingly, the analysis of variation in thyroid function tests 
in healthy volunteers has shown that the physiological individual reference ranges for test 
results are narrow compared with laboratory references (Andersen et al., 2002). This finding 
suggests that a test result within laboratory reference limits is not necessarily normal for an 
individual. Giving that serum TSH responds with logarithmically amplified degree to minor 
changes in serum T4 and T3, abnormal serum TSH may indicate that T4 and T3 are not normal 
for an individual although still within the laboratory references. These data point out that 
the distinction between subclinical and overt thyroid failure (elevated serum TSH and low 
T4 and/or T3) is somewhat arbitrary. Indeed, for the same degree of thyroid function 
abnormality, the diagnosis depends to a considerable extent on the position of the patient’s 
normal set point for T4 and T3 within the laboratory reference range.  
Because sHT is mainly detected as a biochemical TSH abnormality, the definition of the TSH 
reference range represents a critical point, especially in the elderly (Baloch et al., 2003; Olsen, 
1978; Dayan et al., 2001). In the past, the upper normal limit of TSH was considered about 10 
mIU/L with the first-generation TSH RIA assay while, the current normal reference range of 
serum TSH concentration is around 0.45 to 4.5 mIU/L (Biondi & Cooper, 2008; Surks et al., 
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2004).  Considering that serum TSH concentrations in a healthy population have a skewed 
distribution with a "tail" toward higher TSH values, the use of age specific reference limits 
for TSH has been suggested (Surks et al., 2004). This is especially proper in the elderly, in 
whom normal TSH is often shifted to a higher level (Mariotti, 1995) and the clinical 
presentation may differ from that in their younger counterparts (Mohandas, 2003). These 
considerations outline how making a correct diagnosis of sHT is challenging in the elderly 
but crucial to avoid significant misclassification of patients with abnormal TSH, who may or 
may not have thyroid dysfunction and may receive unnecessary or even harmful therapy 
(Laurberg, 2011). Indeed, the clinical significance of sHT in the elderly should be ascertained 
also in relation to the physiological changes of thyroid function with ageing (Biondi & 
Cooper, 2008; Carlè, 2007; Ceresini, 2010; Helfand, 2004; Surks et al., 2004). Therefore, the 
fundamental clinical question regarding these patients is on the clinical significance of sHT 
and the actual need of hormone replacement therapy (Villar, 2007). 
2. Epidemiology  
Several population-based studies have reported that sHT is common in the general 
population, with a prevalence that increases with increasing age (Gharib et al., 2005a,b; 
Hollowell et al., 2002; Samuels, 1998; Tunbridge et al., 1977). In interpreting epidemiologic 
data, it should be taken into account that the ability to identify people with sHT varies by 
TSH assay and cut-off value, which ranged from >3 to >7 mIU/L (Kanaya et al., 2002; Rivolta 
et al., 1999). In this setting, it is noteworthy that some investigators suggest that the upper 
limit of normal for serum TSH level should be 2.5 mIU/L (Spencer et al., 1993). In support of 
this position is a higher prevalence of anti-thyroid antibodies in subjects with serum TSH 
levels >2.5 mIU/L (Vanderpump  et al., 1995). Reasoning about these considerations, it is not 
astonishing that the reported prevalence of sHT in the general population ranges widely 
from 1.3% to 21%, depending on age, gender, and iodine intake (Kanaya et al., 2002; Rivolta 
et al., 1999; Samuels, 1998; Sawin et al., 1985; Tunbridge et al., 1977; Wang et al., 1997).  
In the Wickham survey, the prevalence of sHT (TSH > 6 mIU/L) was 7.5% in women and 
2.8% in men (Wickham study). An age dependent increase in serum TSH concentrations was 
found only when women with high serum anti-thyroid antibody values were included in 
the analysis; with 17.4% prevalence of sHT in women older than 75 years (Wickham study). 
Accordingly, in a Dutch study the prevalence of sHT in a group of middle-aged women 
(mean age 55 years) was 4%, the rate rising to 7.3% 10 years later (Geul et al., 1993). The 
higher prevalence of sHT in older people was confirmed by data from the Framingham 
Study, which reported a prevalence of sHT of 8.2% in men and 16.9% in women, older than 
60 years and, the Colorado study (16% in men and 21% in women older than 74 yrs) (Sawin 
et al., 1979, Canaris et al., 2000). Overall these findings demonstrate that ageing is associated 
with an increased prevalence of positive anti-thyroid antibody titers and mild 
hypothyroidism (Mariotti et al., 1995). The prevalence of sHT varies also according to iodine 
intake; being higher in areas with elevated intake with respect to areas with low-normal or 
deficient intake (Biondi & Cooper, 2012). In this setting,  the occurrence of sHT among 
nursing home elderly residents was 4.2% in an iodine-deficient area (urinary iodine 72 
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micrograms/g creatinine), 10.4% in region of obligatory iodinated salt prophylaxis (urinary 
iodine 100 micrograms/g creatinine) and 23.9% in an abundant iodine intake area (urinary 
iodine 513 micrograms/g creatinine) (Szabolcs et al., 1997).  
Overall, these data show that sHT is a very frequent condition and raise the question of the 
opportunity for general population screening programs, although a consensus is still lacking 
on this topic (Biondi & Cooper, 2012). The above notwithstanding, screening older people 
for thyroid disorders is still suggested by some authorities, aiming at the discovery of 
previously undiagnosed cases of overt hypothyroidism and the monitoring of cases with 
subclinical dysfunction (Ladenson et al., 2000; Surks et al., 2004).  
3. Subclinical hypothyrodism: Clinical features and etiology 
Hypothyroidism is a graded phenomenon that encompasses a wide variety of clinical 
conditions from full blown myxedema to sHT, which is characterized by elevated serum 
TSH concentrations in the face of normal free thyroid hormone levels (Cooper, 2001). 
Currently, the most widely accepted interpretation of these biochemical findings is that 
increased TSH is an indication of slightly reduced peripheral thyroid hormone effect, 
leading to mild hypothyroidism instead of a new steady state of euthyroidism (Karmisholt 
et al., 2011, Ross, 2004). In a consensus statement of the American Association of Clinical 
Endocrinologists, sHT was classified in two categories according to TSH level: mildly 
increased serum TSH levels (4.5–10 mIU/liter), and more severely increased serum TSH 
value (>10 mIU/liter) (Gharib et al., 2005a,b). However, this classification was not adopted in 
all clinical investigations, thus making the comparison of different trials quite difficult.  
There is scientific consensus that sHT is caused by the same etiology of overt 
hypothyroidism (Biondi & Cooper, 2008), the most frequent one being Hashimoto’s 
thyroiditis. This is an autoimmune, inflammatory disorder of the thyroid gland, whose 
prevalence increases with increasing age, being higher in women (Canaris et al., 2000; Surks 
et al., 1996). Other causes of primary hypothyroidism may result from therapies that destroy 
the thyroid tissue such as radioactive iodine treatment, external radiation therapy or partial 
thyroidectomy (Cooper, 2001). Chemotherapy also was associated to hypothyroidism in 
patients with cancer or lymphoma (Hancock et al., 2001; Kumar et al., 2004). Moreover, both 
subclinical and overt hypothyroidism could be induced by many drugs such as amiodarone, 
lithium carbonate, type I interferons, sulfonamides and several other toxic molecules 
(Basaria & Cooper, 2004; Caraccio et al., 2005). 
Patients with sHT have a different rate of progression to clinically overt hypothyroidism in 
the presence or not of autoimmunity: 2.6% each year if thyroperoxidase (TPO) antibodies are 
absent and 4.3% if they are present (Vanderpump et al., 1995). However, a significant number 
of sHT subjects do not show progression and some experiences normalization. One of the most 
predictive markers of progression to overt hypothyroidism is serum TSH level higher than 10 
mIU/L, by contrast a level less than 6 mIU/L depicts a lower likelihood of progression 
(Fatourechi, 2009).  Accordingly, a clinical study, enrolling men and women older than 55 
years with mean follow-up of 32 months, indicated that serum TSH levels normalized in 52% 
of those with serum TSH value less than 10 mIU/L (Díez & Iglesias, 2004).  
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The most common symptoms reported by sHT patients are the same although less evident 
than those observed in overt hypothyroidism: dry skin, poor memory, slow thinking, 
muscle weakness, fatigue, muscle cramp, cold intolerance, puffy eyes, constipation, and 
hoarseness (Canaris et al., 2000; Canaris et al., 1997). It is conceivable that clinical symptoms 
of hypothyroidism are related to the degree of thyroid failure, disease duration, and 
individual sensitivity to thyroid hormone deficiency (Biondi & Cooper, 2008). However, the 
presence of typical symptoms in patients with sHT remains controversial considering that 
many of them are non-specific and shared with many clinical conditions, especially in the 
elderly. Therefore, it is difficult to distinguish euthyroid subjects from sHT patients only by 
using clinical symptoms (Biondi & Cooper, 2008). Baseline data from a randomized clinical 
study confirmed a significant prevalence of hypothyroid symptoms among individuals 
with sHT (Cooper et al., 1984). Moreover, Canaris et al., (2000) reported fewer symptoms 
related to hypothyroidism in subclinical than in overt hypothyroid patients, but more 
frequently than in euthyroid controls. However, this study did not distinguish between 
treated or untreated subclinical and overt hypothyroid patients. By contrast, other cross-
sectional and case-control studies did not confirm these observations, but they were 
conducted among selected or referred populations often involving old hospitalized patients 
(Bemben et al., 1994; Zulewski et al., 1997). Age represents a confounding factor that may 
hinder the identification of symptoms of mild hypothyroidism: the typical findings of 
hypothyroidism are less common in the elderly and, if present, often either resemble or are 
attributed to chronic illnesses, drugs, depression or ageing per se (Billewitc et al., 1969; 
Samuels, 1998). Therefore, clinical signs and symptoms are poor predictors of sHT especially 
in the elderly; this fact may explain why the diagnosis of sHT, and sometime overt disease yet, 
may be delayed in older people (Biondi & Cooper, 2008).  
4. Thyroid function and ageing  
The relationship between thyroid function and ageing has been hypothesized more than one 
decade ago (Mariotti et al., 1995). Human ageing is associated with an increased prevalence 
of serum anti-thyroid antibodies and overt or mild thyroid dysfunction (Hollowell et al., 
2002; Gharib et al., 2005a,b; Samuels, 1998; Tunbridge et al., 1977). Several clinical studies 
confirmed an age-dependent decrease of thyroid function including iodine uptake and 
thyroid hormone production (Hollowell et al., 2002; Gharib et al., 2005a,b; Samuels, 1998; 
Sawin et al., 2009; Tunbridge et al., 1977). Although there is a consensus on the detrimental 
effects of overt hypothyroidism in older patients, the clinical relevance of mild to moderate 
thyroid failure remains an uncertain area (Surks et al., 2004) and, animal models indicated 
that low thyroid hormones are associated to increased life span (Ooka et al., 1983). The 
relative small number of epidemiological studies with inappropriate statistical power, and 
the lack of large prospective randomized trials directed to evaluate the therapeutic effect 
and impact on survival of hormonal therapy in mild thyroid impairment, does not allow to 
conclude whether mild thyroid impairment is a favorable phenotype or a negative clinical 
condition, especially in older people. An age-dependent thyroid dysfunction (particularly 
hypothyroidism) has been well documented in the elderly, including the oldest-old 
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population (>85 yr) (Helfand et al., 2004; Mariotti et al., 1993). An interesting study focused 
on thyroid function during physiological ageing was carried out by Mariotti et al. (1993). In 
this study thyroid status was assessed in 41 healthy centenarians and 33 healthy elderly 
subjects as compared to two control groups: 98 healthy normal adult subjects and 52 
patients with miscellaneous non-thyroidal illness. Healthy centenarians showed a lower 
prevalence of positive anti-thyroid autoantibody titer than elderly controls with a relatively 
low (7%) prevalence of sHT although the median serum FT3 level was lower than in each 
other group. Interestingly, median serum TSH level of centenarians was lower than in 
healthy elderly subjects, in whom however, was significantly lower than in young controls 
(Mariotti et al., 1993). This study did not resolve the question whether the decreased FT3 and 
TSH value observed in healthy centenarians, represents an adaptive mechanism to reduced 
metabolic homeostasis or a protective condition in ageing. At partial odds with these data, a 
population based survey and one large cross-sectional study (Atzmon et al., 2009; Surks et 
al., 2007) showed a progressive shift of the normal serum TSH range towards higher values 
from healthy young individuals up to centenarians. Overall these data seem to suggest that 
ageing is associated with a certain degree of down regulation of the hypothalamus-
pituitary-thyroid-peripheral axis, although the clinical significance of such condition is far to 
be elucidated. To this regard, Rozing et al. (2010) reported that the offspring of 
nonagenarian siblings presented a lower thyroidal sensitivity to TSH and a paradoxical 
beneficial cardiometabolic profile as compared to their partners. The authors concluded that 
the favorable role of low thyroid hormone metabolism on health and longevity, already 
observed in animal models, might be applicable to humans as well. However, the study by 
Rozing et al. (2010) enrolled a specific population in order to identify familial determinants 
of healthy longevity in nonagenarian siblings.  The results might, therefore, be affected by 
some bias and cannot be extended to the general population. On the other hand, a cross-
sectional study by Corsonello et al. (2010) carried out in 604 home-dwelling subjects born in 
Calabria (southern Italy), with ancestry in the region ascertained up to the grandparents, 
confirms a declining of serum thyroid hormone levels with ageing. Moreover, lower levels 
of FT3, FT4 and TSH were found in centenarians’ children and nieces/nephews with respect 
to age-matched controls. Indeed, the authors conclude that an age-related subtle decline of 
thyroid function (either due to a familial component or due to a reset of the thyroid function 
occurring between the sixth and the eighth decade of life) seems to be related to longevity. 
Two other studies support the hypothesis that mild hypothyroidism in elderly might be 
associated to a better survival and performance status.  In the first, Gussekloo et al. (2006) 
found lower all-cause and cardiovascular mortality in hypothyroid subjects aged more than 
85 years followed for 4 years, when compared with euthyroid individuals. In the second, 
van den Beld et al. (2005) showed that low-serum T3 (with normal rT3) concentrations were 
associated with a better survival and physical performance, while subjects with low-serum 
T3 and high rT3 concentrations (“low T3 syndrome”) did not show any survival advantage 
and had lower baseline physical activity. The authors suggested that higher serum rT3 
concentrations may result from a decreased peripheral metabolism of thyroid hormones due 
to the ageing process itself and/or disease and may reflect a catabolic state although, a 
certain degree of lower activity of the thyroid hormone axis might be beneficial during the 
aging process.  
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All together, these findings might support the idea that mild physiologically decline of 
thyroid activity at the tissue level might have favorable effects in the oldest-old subjects. 
However, the interpretation of the predictive value of thyroid failure in old subjects has to 
be considered with caution, carefully defining the context and the criteria of analyzed 
populations. In this setting, the comparison of observational trials is not so easy and the 
different population analyzed should be taken into account. Indeed, there is not a unique 
definition of TSH limits for patient classification in the clinical studies or statistical analysis, 
and the population of published trials is very heterogeneous differing for the age of enrolled 
patients, life styles, comorbidities, treatments, ethnics etc. Although in some selected elderly 
subjects (specific ethnic population or very old subjects) (subtle) thyroid failure might be a 
beneficial factor or a longevity associated character, one of the most debated issues 
regarding the health consequences of (subclinical) hypothyroidism in the elderly is 
represented by the potential increase of ischemic heart disease (IHD) or other CVDs as well 
as cognitive impairment (Mariotti et al., 2005).  
5. Subclinical hypothyroidism and cardiovascular diseases  
5.1. Pathophysiology  
The most characteristic and common symptoms and signs, experienced by patients with 
thyroid disease, are those related to the cardiovascular (CV) system (Klein & Ojamaa, 2001). 
Both hyperthyroidism and hypothyroidism produce changes in cardiac contractility, 
myocardial oxygen consumption, cardiac output, blood pressure, and systemic vascular 
resistances (SVR) (Dillmann, 2002). Indeed, either hyper or hypothyroidism can produce 
heart arrhythmias, although it is less well recognized that hypothyroidism may predispose 
to specific dysrhythmias (Klein & Danzi., 2007). Cardiovascular signs and symptoms of 
hypothyroidism include bradycardia, mild (diastolic) hypertension, narrowed pulse 
pressure, cold intolerance, and fatigue (Klein & Ojamaa, 2001).  
Subclinical hypothyroidism might be interpreted as an intermediate alteration between 
overt dysfunction and euthyroidism, consequently, the modifications of CV system 
observed in sHT qualitatively resemble those produced by overt hypothyroidism even if 
less evident. Accordingly, several evidences indicated that there is a direct association 
between serum TSH value and CV alterations as well as blood pressure, cholesterol level 
etc. (Biondi & Cooper, 2008; Asvold et al., 2007). There are many evidences that, in major 
part of the cases of thyroid patients, cardiovascular changes are reversible when the 
underlying thyroid disorder is recognized and treated (Kahaly et al., 2005). Moreover, there 
is substantial evidence that overt hypothyroidism and also sHT, although to a lesser extent, 
may alter several of the traditional risk factors for ischemic CVD.  
The effects of thyroid hormone deficiency on the cardiovascular system have been evaluated 
from many points of view as heart diastolic and systolic dysfunction, endothelial 
dysfunction, hypertension, metabolic alterations and impaired exercise performance (Biondi 
& Cooper, 2008). To understand well the impact of sHT on CV system and the consequent 
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increased risk of cardiovascular  events, it is necessary to review the molecular effects of T3 
and T4, and the modifications that they exert in myocytes, endothelium, vascular muscle 
cells, intermediate metabolism etc. The decrease of cardiac output associated with 
hypothyroidism results, in part, from changes in cardiac gene expression, specifically 
reduced expression of the sarcoplasmic reticulum Ca2-ATPase, and increased expression of 
its inhibitor, phospholamban (Belke et al., 2007). In addition, these molecular changes 
explain the prolonged isovolumic relaxation phase of the hypothyroid myocardium and 
early reversible diastolic impairment (Klein & Danzi, 2007). Interestingly, this mechanism 
functionally resembles the progressive age related myocardium modification, in which 
increased fibrosis, myocyte hypertrophy and myocyte loss result in increased myocardial 
stiffness leading to diastolic heart failure (Biondi & Cooper, 2008). 
Triiodothyronine produces a decrease in systemic vascular resistance enhancing arteriole 
dilatation of the peripheral circulation (Klein & Ojamaa, 2001). The endothelium and smooth 
muscle cells are biological targets of action of T3 with a vasodilatation effect, also in coronary 
arteries (Ojamaa et al., 1996). As stated by Klein & Ojamaa (2001), T3 induces in vitro 
relaxation of smooth muscle cells with a non-genomic effect and independently of nitric 
oxide production (Klein & Ojamaa, 2001). Indeed, Ojamaa et al. (1996) found that the 
exposure of primary cultures vascular smooth muscle cells to T3 resulted in cellular 
relaxation within 10 min while, the exposure of primary cultures of vascular endothelial 
cells to the same hormone did not induce nitric oxide production, suggesting a direct effect 
of T3 on vascular smooth muscle cells. By contrast, Colantuoni et al. (2005) showed that in 
vivo thyroid hormone induced vasodilatation is delayed and mainly dependent to nitric 
oxide. The aim of their study was to assess the effects of topically applied T3 and T4 on the 
arterioles of hamster cheek pouch microcirculation in vivo by visualizing microvessels 
through a fluorescent microscopy technique. Topical application of both T3 and T4 
consistently induced a dose-dependent dilation of arterioles within few minutes. However, 
T3-induced dilation was countered by the inhibition of nitric oxide synthase with specific 
iNos inhibitors. These discrepancies between in vitro and in vivo findings might be related to 
differences in experimental procedures and to the fact that in vivo conditions are more 
complex than in vitro insolated cell cultures (Galli et al., 2010). The vascular action of T3 and 
T4 has been also reported to be associated with the modulation of gene expression related to 
endothelial homeostasis like angiotensin receptors (Fukuyama et al., 2003), reinforcing the 
hypothesis that thyroid hormones mainly target the vasculature. Accordingly, a cross-sectional 
study on 30728 patients without previous known thyroid diseases revealed a linear positive 
association between TSH level and systolic and diastolic blood pressure (Asvold et al., 2007). 
In this setting, Fommei et al. (2002) reported the physiological relationships between blood 
pressure and neuro-humoral modifications induced by acute hypothyroidism [levothyroxine 
(LT4) withdrawal] in normotensive subjects. During the hypothyroid state daytime arterial 
blood pressure (mainly diastolic) significantly increased along with noradrenaline and 
adrenaline levels. By contrast, plasma renin activity remained unchanged. These data, besides 
confirming the role of thyroid hormones in systemic arterial blood pressure homeostasis, 
suggest that sympathetic and adrenal reversible activation may contribute to the development 
of arterial hypertension in human hypothyroidism (Fommei et al., 2002).  
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Arterial hypertension related to thyroid hormone deficiency may result in aortic stiffness 
and early atherosclerosis. In this setting, aortic stiffness was studied in 30 patients who 
never received treatment for hypertension or hypothyroidism, 15 patients with normal 
blood pressure and hypothyroidism, and 15 patients with hypertension and normal thyroid 
function. Aortic diameter, evaluated by M-mode echocardiography and blood pressure 
measured by sphygmomanometer, were assessed to calculate the aortic stiffness index. 
Patients with hypertension and hypothyroidism have increased aortic stiffness, which was 
decreased in all patients by hormone replacement therapy, although hypertension resulted 
completely reversible in 50% of the patients (Dernellis et al., 2002).  In addition, it has been 
hypothesized that thyroid hormone deficiency might be related to endothelial dysfunction. 
In this area, Lekakis et al. (1997) enrolled 35 subjects with various serum TSH levels to assess 
endothelial and smooth muscle responses of the brachial artery by high-resolution 
ultrasound imaging. Results of this study showed that flow-mediated, endothelium-
dependent (FMD) vasodilatation progressively impaired with increasing serum TSH value; 
the phenomenon appearing still in patients with TSH value within the normal reference 
range (2.01-4.00 microIU/mL) (Lekakis et al., 1997). Furthermore, in order to assess vascular 
reactivity and NO availability in patients with sHT and its relation to the serum lipid 
profile, Taddei et al. (2003) evaluated, by strain-gauge plethysmography, the forearm blood 
flow response to intrabrachial acetylcoline, an endothelium-dependent vasodilator, at 
baseline and during infusion of the eNO synthase inhibitor Ng-monomethyl-L-arginine (L-
NMMA). Results from sHT patients were compared with two groups of euthyroid control 
subjects, one with normal lipid profile and one with mildly elevated serum TC levels, 
comparable to those of sHT patients. They found that vasodilation in response to 
acetylcholine of patients affected by sHT was reduced as compared to that of both groups of 
euthyroid control subjects. Similarly, L-NMMA blunted the vasodilation in response to 
acetylcholine either in normolipemic or in mildly hypercholesterolemic controls, whereas it 
was ineffective in sHT patients, thus suggesting a reduced NO availability due to impaired 
NO synthase induced by sHT per se. Interestingly, six months of euthyroidism induced by 
LT4 replacement increased acetylcholine vasodilation and restored L-NMMA inhibition. 
Subsequently, the same group (Taddei et al. 2006) demonstrated that endothelial 
dysfunction of a cohort of sHT patients with autoimmune thyroiditis was, at least partially, 
related to oxidative stress and low-grade systemic inflammation. Indeed, sHT patients had 
higher plasma C-reactive protein (CRP) levels as compared to euthyroid controls, and 
endothelium dysfunction was significantly improved after either local infusion of vitamin C 
or systemic administration of indomethacin, a non-selective cyclo-oxygenase (COX) 
inhibitor. Comparable results were obtained after administration of celecoxib, a selective 
COX-2 inhibitor, thus suggesting that an association between thyroid function and low-
grade systemic inflammation could be postulated. Accordingly, several studies (Kvetny et 
al., 2004; Luboshitzky et al., 2004; Christ-crain et al., 2003; Lee et al., 2004) investigated the 
possible relationship between TH deficiency and serum CRP level, that was mostly found 
higher in hypothyroid patients, although unaffected by LT4 therapy (Christ-crain, 2003).    
Another concurring factor for developing early atherosclerosis in hypothyroidism is 
represented by the metabolic alterations induced by hormone deficiency. Hypothyroidism is 
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characterized by hypercholesterolaemia with elevation of low-density lipoprotein 
cholesterol (LDLc) levels because of decreased fractional clearance of LDLc by a reduced 
number of the receptors in the liver (Duntas et al., 2002; Staub et al., 1992). Early studies in 
hypothyroid humans, using isotopically labeled LDLc, demonstrated a prolonged half-life 
of LDLc due to a decreased catabolism; this effect was reversible with LT4 therapy (Walton 
et al., 1965). Accordingly, the addition of T3 to human fibroblast cultures induced a higher 
LDLc degradation, through an increase in LDLc receptor number, without any receptor 
affinity change (Chait et al., 1979). Molecular mapping has revealed functional thyroid 
response elements in the promoter region of the LDLc receptor. Indeed, specific stimulation by 
T3 of a chimeric gene resulting from the LDLc receptor promoter linked to a reporter gene, 
cotransfected with the isoform of the thyroid hormone receptor into a hepatic cell line, has 
been reported (Bakker et al., 2001). Moreover, the deletion of the upstream thyroid response 
elements in the LDLc receptor promoter inhibited T3-mediated reporter gene activity (Cappola 
et al., 2003). Although the relationship between thyroid function and altered lipid profile is 
well documented in overt hypothyroidism it is still controversial in sHT (Biondi & Cooper, 
2012). The conflicting results about lipid profile and sHT might reflect differences in study 
design as well as in age, gender, and ethnicity of the study cohorts (Palmieri et al., 2002).  
Various changes in the coagulation-fibrinolytic system have been described in patients with 
thyroid dysfunction although, data regarding the association between thyroid failure and 
modifications of the coagulation-fibrinolytic system are still controversial (Chadarevian et 
al., 2001; Canturk et al., 2003; Muller et al., 2001). The influence of thyroid hormone on the 
coagulation fibrinolytic system is mainly mediated by the interaction between the hormone 
and its receptors (Shih et al., 2004). Various abnormalities have been described, ranging 
from subclinical laboratory abnormalities to major hemorrhages or fatal thromboembolic 
events (Squizzato et al. 2007). The relationship between thyroid hormones and the 
coagulation system is, however, often ignored. One of the reasons could be that, although 
several in vivo abnormalities have been reported in patients with hypothyroidism and 
hyperthyroidism, most published studies focus on laboratory measurements, and good 
studies on the relationship between thyroid dysfunction and clinically manifest bleeding or 
thrombosis are lacking. However, most studies confirm that both overt hyper- and 
hypothyroidism modify the coagulation-fibrinolytic balance. Thyroid hormone excess or 
deficit is the probable main pathophysiological mechanism and, patients with overt hypo- 
and hyperthyroidism appear to have an increased risk of bleeding and of thrombosis, 
respectively (Squizzato et al. 2007). 
Overall, these findings support a biologically plausible role for hypothyroidism in 
increasing the risk of atherosclerotic CV disease, via the increase in circulating levels of 
LDLc, systemic (diastolic) hypertension, diastolic dysfunction and heart failure as well as an 
imbalance of the coagulation system and direct effects on vascular smooth muscle (Cappola 
et al., 2003). However, the actual relationship between sHT and increased cardiovascular 
risk is still unresolved and represents one of the most common topics in endocrinology, 
leading to several controversies concerning the clinical management of sHT patients 
(Turemen et al., 2011). 
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5.2. Clinical evidences   
As above described, thyroid hormone deficiency is associated to several cardiovascular and 
metabolic abnormalities (Biondi & Cooper, 2008; Caraccio et al., 2003; Dardano & Monzani, 
2008). Indeed, thyroid failure may favour the onset of several CV risks like diastolic 
hypertension, hyperlipidemia, vascular stiffness, heart failure etc. However, although the 
relationship between overt hypothyroidism and coronary heart disease (CHD) as well as 
increased CHD mortality is widely recognized (Klein, 2004), the clinical significance of sHT 
is still controversial and conflicting opinions remain on the association between sHT and 
CVD or mortality, especially in older people (Biondi & Cooper, 2008; Monzani et al., 2006). 
Indeed, data regarding the association between sHT and CHD or total mortality are 
contradictory among various population based, observational studies (Aho et al., 1984; 
Cappola et al., 2004; Hak et al., 2000; Walsh et al., 2005).  
One of the first large study (Whickham Survey) that evaluated vascular events over 20 years 
in community-dwelling subjects stratified by thyroid function and thyroid autoantibody 
status did not show any association between CHD and sHT (Vanderpump et al., 1995). This 
result appeared at odds with the findings of other subsequent cohort studies (Hak et al., 
2000; Imaizumi et al., 2004; Walsh et al., 2005). However, while reanalyzing incident CHD 
events and mortality in Whickham participants including LT4 replacement during follow-up 
as covariate, a significant increment of incident CHD events and mortality was found in 
individuals with baseline sHT (Razvi et al., 2010). Based on the results of this analysis, it 
would appear that treatment of sHT might be associated with reduced mortality as well as 
CHD events. However, besides the small total number of events in each group of sHT 
participants, there is a potential for bias in this retrospective observational analysis (i.e. sHT 
patients who were treated may have been more health conscious leading to a healthy user 
bias). Therefore, these results need to be interpreted with caution until a large prospective, 
randomized controlled trial will be available. The inconsistency in results among several 
studies (Aho et al., 1984; Hak et al., 2000; Cappola et al., 2004; Razvi et al., 2010; Walsh et al., 
2005) may be due to differences in the enrolled populations as well as the duration either of 
tissues exposure to sHT or of follow-up of the various studies. Nonetheless, meta-analyses 
of CHD events and sHT have shown that such an association probably exists (Razvi et al., 
2008; Rodondi et al., 2006), especially in younger cohorts. In this regard, to assess the risks of 
CHD and total mortality for adults with sHT, Rodondi et al. (2010) carried out a large meta-
analysis on 11 prospective cohorts, enrolling a total of 55,287 participants. The risk of CHD 
events was examined in 25,977 participants from 7 cohorts with available data. Among 
55,287 adults, 3450 had sHT (6.2%) and 51,837 were euthyroid. The Authors found that the 
risk of CHD events and mortality increased with higher TSH concentrations. Results were 
similar after adjustment for traditional cardiovascular risk factors. Moreover, this pooled 
analysis showed a higher rate of CHD events in sHT patients with higher TSH levels (>10 
mIU/L). These data are consistent with most previous meta-analysis and several naturalistic 
studies, showing an increased risk of CHD events associated with sHT (Hak et al., 2000; 
Singh et al., 2007; Walsh et al., 2005).  
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These studies, however, did not accurately explore potential differences related to 
participant characteristics like age, even if older people represented large a share of the 
population. In this setting, the pooled analysis of large cohort of patients may be affected by 
hypothetical bias and may not investigate specific classes of patients like very old people 
versus moderate elderly patients or other specific conditions affecting the clinical outcome. 
Ochs et al. (2008) analysed in a meta-analysis the effect of ageing on sHT associated CV 
events and total mortality. Similar to previous meta-analysis, they found a pattern of 
modestly increased risk for CHD and mortality associated with sHT. A weak evidence for 
statistical heterogeneity among individual study findings was found, and age explained part 
of the heterogeneity for the association between sHT and CHD, with an increased risk for 
CHD only in cohorts with a younger mean age. Accordingly, Cappola et al. (2006), in a large 
population-based, longitudinal study of coronary heart disease and stroke in adults aged 65 
years and older, concluded that the results did not support the hypothesis of an association 
between unrecognized sHT and increased CV events or mortality. On the other hand, one 
cross-sectional study with subgroup analyses by age found that increased risk for CHD was 
present in younger sHT participants only (<50 years old) (Kvetny et al. 2004). In this regard, 
a prospective, observational, population-based follow-up study carried out on 599 
participants followed up from age 85 years through age 89 years showed no association 
between serum TSH and FT4 levels and disability in daily life, depressive symptoms, and 
cognitive impairment at baseline or during follow-up. Moreover, increasing serum TSH 
levels were associated with a lower mortality rate that remained after adjustments for 
baseline disability and health status (Gusseklo et al. 2004). Overall, these data support the 
hypothesis that in the oldest old population, individuals with abnormally high levels of TSH 
do not experience adverse effects and may have a prolonged life span. The study focused on a 
specific class of patients (very older people), for this reason, the results should be rigorously 
interpreted, also considering the weakness of observational studies. However, these data 
together with the results obtained by Rozing et al., (2010) that demonstrated a possible genetic 
predisposition of nonagenarians to a decrease function of hypothalamus-pituitary-thyroid 
axis, suggest that the oldest old may represent a different population respect to moderate old 
people or young adults. Potential explanations for these age differences might be competing 
mortality among older adults (for example, due to cancer) or more competing risk factors for 
CHD among older adults (for example, age or sex). However, the above reported substantial 
age differences should be interpreted with caution, given the possibility of ecological fallacy 
without individual patient data and, should be confirmed by stratified analyses in future 
prospective cohort studies with a wide age range (Egger et al., 2001).  
There are few clinical studies evaluating the effects of hormone replacement in sHT subjects 
and none aimed to determine the impact of therapy on total mortality especially in older 
people. Previous research in this area has shown contradictory results, with some 
randomized, controlled trials (number of patients ranging from 45 to 63) showing an 
improvement in the atherogenic lipid profile as well as surrogate endpoints of 
atherosclerosis (Meier et al., 2001; Caraccio et al., 2002; Monzani et al., 2004) but others 
(number of patients ranging from 17 to 35) showing no difference (Cooper et al., 1984; 
Jaeschke et al., 1996; Kong et al., 2002; Nystrom et al., 1988). Recently, Razvi et al. (2007) 
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conducted a randomized, double-blind, crossover study to determine the short-term (12 
weeks) effect of LT4 replacement therapy in 100 sHT patients (age range 18-80 yrs, mean 
53.8) with serum TSH level>4.0 mIU/L. Primary end points included: serum cholesterol level 
variations along with improvement in flow-mediated dilation (FMD) as a marker of 
vascular endothelial function. LT4 treatment significantly reduced either TC or LDLc 
concentrations, and improved FMD, as compared to placebo group. Moreover, multivariate 
analysis showed that increased serum FT4 level was the most significant variable predicting 
reduction in TC or FMD improvement. The Authors hypothesized that if the reduction of 
LDLc level would be long term sustained, this would result in a relative reduction in 10-yr CV 
mortality of about 10%, thus supporting the use of LT4 replacement therapy also in patients 
with slightly elevated TSH value. Long-term studies are nonetheless required to confirm 
whether these apparent short-term benefits will translate into reduction in CV mortality and 
morbidity. Moreover, notwithstanding the wide age range of the studied patients, these results 
cannot directly transfer to the elderly, especially the oldest old population. 
In summary, conflicting results among large prospective cohort studies regarding the 
relationship between sHT and cardiovascular disease might reflect differences in 
participants such as age, gender, TSH value, or pre-existing cardiovascular disease. 
However, as demonstrated by some meta-analyses, the negative effect of sHT on 
cardiovascular risk is well established in younger people while in moderately old 
population (>65 and <85 years) it appears no longer evident.  Moreover, in the oldest old 
people (>85 years) one study suggested that high levels of TSH not only do not exert adverse 
effects but also may favor a prolonged life span (Fig. 1). In this regard, elderly population 
can be interpreted as a heterogeneous group, nonagenarians representing a genetically 
selected cluster. Indeed, these subjects may have a genetic background that protects from 
CVD and/or thyroid hormone deficiency, thus suggesting an intriguing link between gene, 
thyroid status and longevity. 
6. Thyroid function and cognitive impairment   
Thyroid hormones are crucial for brain development and function: thyroid failure at any age 
causes cognition to deteriorate because thyroid hormones are essential for adequately 
sustaining the energy (glucose)-consuming processes needed for neurotransmission, 
memory, and other higher brain functions (Herholz, 2010; Patel et al., 2011). Low brain 
uptake of glucose is commonly associated with deteriorating cognition and Alzheimer’s 
disease and can be present decades before clinical evidence of Alzheimer’s disease occurs 
(Herholz, 2010). Brain hypometabolism therefore appears to be a precursor lesion increasing 
the risk of at least some forms of cognitive decline. Elevated TSH levels in the range found 
in patients with overt hypothyroidism have been described to be associated with impaired 
function in many cognitive domains, but the association between sHT and cognition is less 
clear (Graham et al., 1997; Gardner, 2004; Chavanne et al., 2011). On the other hand, several 
cross-sectional studies have observed that high or low TSH levels, still within the normal 
range (clinically euthyroid), are each related to poor cognitive performance, although some 
other investigations failed to demonstrate these findings (Prinz et al., 1999; Volpato et al., 
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2002). It should be underlined, however, that different cognitive deficits possibly related to 
thyroid failure do not necessarily follow a consistent pattern, and LT4 treatment may not 
always completely restore normal functioning in patients with hypothyroidism. Giving 
these premises, we summarize here the growing, conflicting literature on the relationship 
between cognitive performance and thyroid function from an ageing perspective.  
 
Figure 1. Hypothetical relationship between risk of total mortality and age in patients with subclinical 
hypothyroidism (sHT) (Modified from Mariotti, 2005). 
Subclinical hypothyroidism and cognitive function have been investigated in several 
preclinical experiments and clinical trials. To date, the actual relationship between mild 
thyroid hormone deficiency and cognitive impairment in the elderly is not well understood. 
In fact, there are several contrasting data resulting from cross-sectional and clinical 
experiments (Gussekloo et al., 2004; Roberts et al., 2006; Tan et al., 2008; Ceresini et al., 2009). 
Moreover, the available published data, in many cases, are not easily comparable 
considering the differences in inclusion criteria of each clinical study. Several small 
observational and interventional studies have reported an association, although not 
homogeneously, between cognitive impairment and sHT and, in some cases, it was 
described a cognitive performance improvement after LT4 replacement (Etgen et al., 2011; 
Monzani et al., 1993; Osterweil et al., 1992; St. John et al., 2009; Volpato et al., 2002). 
Moreover, Hogervost et al. (2008) studied the association between TSH and FT4 levels and 
cognition at baseline and after 2 years of follow-up in 1047 participants over 64 years of age, 
without physical frailty or severe cognitive impairment. The study showed that elevated 
TSH levels were associated with lower MMSE performance at baseline, independently of 
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FT4 value, age, sex, education and mood. Interestingly, epidemiological surveys using the 
revised Wechsler Adult Intelligence Scale (WAIS-R) and the Mini-Mental State Examination 
(MMSE) showed a relationship between plasma thyroid hormone levels and cognitive status 
in subjects with thyroid function still within the upper limit of the normal range (Prinz et al., 
1999; Volpato et al., 2002). Accordingly, altered plasma thyroid hormone concentrations 
have been recognized as a risk factor for cognitive impairment or dementia (Bulens, 1981; 
Kalmijn et al., 2000; Tan et al., 2008). More specifically, with the increasing sensitivity of 
neuropsychological tools, it has become evident that thyroid hormone deficiency might 
produce measurable deficits in very specific neuropsychological functions (Zoeller & Rovet 
2004). In this regard, in a recent prospective, open-labeled interventional study, cognitive 
impairment associated with (mild) thyroid failure appeared predominantly mnemonic in 
nature, suggesting that the etiology is not indicative of general cognitive slowing (Correia et 
al., 2009). 
Conflicting data were obtained by large, population-based studies, leading to uncertain 
conclusions regarding the association between (mild) thyroid failure and cognition 
(Gussekloo et al., 2004; Roberts et al., 2006; Tan et al., 2008; Ceresini et al., 2009). In this 
setting, one critical point that could affect the results of these studies is the diverse age 
groups of the enrolled patients (moderate or very old) as well as the presence of 
comorbidity. Cognitive impairment observed in older sHT individuals might be also an 
epiphenomenon of the increased risk for atherosclerosis or the effect of thyroid hormone on 
vasculature. Indeed, arterial stiffness is a potential mechanism of advancing cognitive 
decline in sHT (Yamamoto et al., 2012) and elevated TSH values might negatively affect 
vascular function through systemic low-grade inflammation (Taddei et al., 2006). Moreover, 
whereas in moderate older people sHT might produce a detrimental effect on cognitive 
performance, in very old individuals (mild) thyroid failure might be not associated to a 
negative outcome (Gussekloo et al., 2004; Tan et al., 2008). To determine whether subclinical 
thyroid dysfunction should be treated in old age and the long-term impact of thyroid 
dysfunction on performance and survival in the elderly, a prospective, observational, 
population-based survey was carried out within the Leiden 85-Plus Study. A total of 599 
participants were followed up from age 85 years through age 89 years. Plasma levels of TSH 
and FT4 were not associated with disability in daily life, depressive symptoms, and cognitive 
impairment at baseline or during follow-up. Conversely, increasing levels of TSH were 
associated with a lower mortality rate that remained after adjustments were made for 
baseline disability and health status (Gussekloo et al., 2004). It is noteworthy, however, that 
similarly to CHD risk, these results should be confirmed by stratified analyses in future 
prospective large cohort studies with a wide age range.  
Another important aspect is the possible relationship between sHT and the risk to develop 
Alzheimer disease (AD). On this basis, many studies investigated a possible association 
between AD and thyroid dysfunction. Increasing evidence supports an extensive 
interrelationship between thyroid hormones and the cholinergic system, which is selectively 
and early affected in AD. Thyroid hormones negatively regulate expression of the amyloid-
beta protein precursor, which plays a key role in the development of AD (Belakavadi et al., 
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2011). In a study aimed to examine the feasibility of using thyroid hormone as a therapeutic 
agent for AD, mice were injected intra-hippocampally with aggregated amyloid beta-
peptide (Abeta) to produce AD animal model. Intraperitoneal administration of LT4 into 
Abeta-induced AD model mice prevented their cognitive impairment and improved their 
memory function. The authors suggested that the mechanisms of LT4 treating AD might be 
associated with regulating cholinergic function, protecting the brains of AD model mice 
against damage and rescuing hippocampal neurons from apoptosis. The results of this study 
seem indicate that the use of thyroid hormone may have some therapeutic potential in AD 
(Fu et al., 2010).  Accordingly, in a post mortem study it was evaluated the brain thyroid 
hormone levels in AD measured with radioimmunoassay (RIA) samples of prefrontal cortex 
of patients with pathologically confirmed AD and controls without any primary 
neurological disease. Thyroxine levels did not differ between groups while T3 levels were 
significantly lower in Alzheimer’s brains respect to controls. These results suggest that the 
conversion of T4 to T3 may be altered in advanced AD, perhaps due to modifications in 
deiodinase activity, and the reduced hormone conversion might be associated with both AD 
pathology and the clinical presentation of dementia (Davis et al., 2008). Moreover, Tan et al. 
(2008) related serum TSH concentrations to the risk of Alzheimer disease in 1864 cognitively 
intact, euthyroid participants of the Framingham original cohort (mean age 71 years). 
During a mean follow-up of 12.7 years, 209 participants (142 women) developed AD. 
Women in the lowest (<1.0 mIU/L) and highest (>2.1 mIU/L) tertiles of serum TSH 
concentration were at increased risk for AD compared with those in the middle tertile while, 
TSH levels were not related to AD risk in men. On the other hand, at odds with these 
findings, the InChianti study showed an association between subclinical hyperthyroidism 
and cognitive impairment without any correlation with mild thyroid failure in a large cohort 
of older people (Ceresini et al., 2009).  
In conclusion, a certain degree of cognitive (mnemonic) impairment is generally recognized 
in case of overt hypothyroidism while, the relationship between cognition and sHT is still a 
disputed field, and it remains unclear whether to treat or not this kind of patients. In 
particular, there is little or no consensus in the literature whether thyroid failure is 
associated with impaired cognitive performance in the elderly, especially in the oldest old 
population. While interpreting the above reported conflicting results it should be outlined, 
however, that thyroid hormone concentrations change with age and cognitive decline is 
often concomitant with ageing; therefore, a reciprocal relationship could exist between 
changes of thyroid function and cognitive decline during normal ageing. 
7. Conclusions 
Levothyroxine replacement therapy for reducing sHT associated CV risk factors is still 
controversial, especially in the elderly. The lack of specific randomized trials, enrolling 
either old or very old subjects, aimed to evaluate the efficacy of hormonal replacement on 
overall survival and cardiovascular risk reduction as well as the possible negative effects of 
LT4 supplementation, makes the decision to treat elderly people very difficult. Generally, 
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LT4 replacement therapy should be considered for three main reasons: i) to prevent 
progression of sHT to overt hypothyroidism which, however, is much more important in 
young patients; ii) to reduce the symptoms associated with mild thyroid failure, which are 
especially scarce in the elderly; iii) to improve the lipid profile and other risk factors that 
may contribute to atherosclerosis progression and CV events.  
Subclinical thyroid failure causes changes in cardiac function similar to, but less marked 
than, those occurring in patients with overt hypothyroidism. Diastolic dysfunction both at 
rest and upon effort is the most consistent cardiac abnormality in patients with sHT, even in 
those with slightly elevated TSH levels (>6 mIU/L) (Arem et al., 1996; Biondi & Cooper, 
2012;). Mild thyroid failure may also increase diastolic blood pressure as a result of 
increased systemic vascular resistances (Faber et al., 2002; Kahaly, 2000; Luboshitzky et al., 
2002). Interestingly, restoration of euthyroidism by LT4 replacement is able to reduce 
systemic hypertension as well as improve left ventricular myocardial function (Brenta et al., 
2003). Moreover, sHT has been claimed to be a risk factor for atherosclerosis and ischemic 
CVD, therefore, it is appropriate to consider whether treatment confers some protection 
from such a risk. Although a consensus is still lacking, the strongest evidence for a beneficial 
effect of levothyroxine replacement therapy is the substantial demonstration that restoration 
of euthyroidism can lower TC and LDLc levels in most patients with sHT. Besides 
hypercholesterolemia several emerging risk factors for CHD have been claimed to be 
associated with sHT. Among them, altered coagulation parameters, endothelial dysfunction, 
and elevated CRP levels are consistently regarded to combine with the raised LDLc levels of 
untreated patients with sHT to enhance the cardiovascular risk.  
As a whole, these findings suggest that the decision to treat patients with sHT should 
depend on the presence of risk factors, rather than on a TSH threshold. International 
organizations and guidelines suggest starting replacement therapy in patients who have 
TSH concentrations greater than 10 mIU/liter and in those with evidence of autoimmunity, 
and in symptomatic patients with TSH levels between 4.5 and 10 mIU/L (Gharib et al., 
2005a,b; Surks et al., 2004). However, the treatment of sHT patients, especially the elderly, 
must be individualized once any underlying coexisting morbidity or pharmacologic 
interference has been excluded. Generally LT4 replacement results effective and safe in 
young patients, providing that excessive dosing is avoided by monitoring serum TSH level. 
Indeed, LT4 replacement therapy can always be discontinued if there is no apparent benefit. 
It is noteworthy that, once a stable, elevated TSH value is detected, the costs of annual 
follow-up with clinical assessment and laboratory testing are relatively similar whether or 
not a patient is treated with LT4 (Cooper et al., 2001). On the other hand, the possibility that 
restoring euthyroidism may be harmful in the older population has been raised, and should 
be taken into account in making the decision of treating such patients, especially those older 
than 85 years. In this setting, hormonal replacement might be considered in old patients on 
the base of a specific evaluation of the possible thyroid dysfunction causes, pre-existent 
cardiovascular risk including cholesterol level, hearth failure as well as the presence of 
comorbidities or frailty and the level of TSH. However, until adequate data are 
accumulated, clinicians should consider each patient a unique situation, and best clinical 
practice continues to be a combination of clinical judgment and the patient’s preference. 
 
Mild Thyroid Deficiency in the Elderly 199 
Author details 
Giuseppe Pasqualetti, Angela Dardano, Sara Tognini, Antonio Polini and Fabio Monzani 
Geriatrics Unit, Department of Internal Medicine, University of Pisa, Italy 
8. References 
Aho, K., Gordin, A., Palosuo, T., Punsar, S., Valkeila, E., Karvonen, M., Inkovaara, J., 
Pasternack, A. (1984). Thyroid autoimmunity and cardiovascular diseases. Eur Heart J, 
Vol. 5, No. 1 (Jan 1984), pp. 43-46, issn  0195-668X (Print) 0195-668X (Linking). 
Andersen, S., Pedersen, K.M., Bruun, N.H., Laurberg, P. (2002). Narrow individual 
variations in serum T(4) and T(3) in normal subjects: a clue to the understanding of 
subclinical thyroid disease. J Clin Endocrinol Metab, Vol. 87, No. 3 (Mar 2002), pp. 1068-
1072, issn  0021-972X (Print) 0021-972X (Linking). 
Arem, R., Rokey, R., Kiefe, C., Escalante, D.A., Rodriguez, A. (1996). Cardiac systolic and 
diastolic function at rest and exercise in subclinical hypothyroidism: effect of thyroid 
hormone therapy. Thyroid, Vol. 6, No. 5 (Oct 1996), pp. 397-402, issn  1050-7256 (Print) 
1050-7256 (Linking). 
Ashizawa, K., Imaizumi, M., Usa, T., Tominaga, T., Sera, N., Hida, A., Ejima, E., Neriishi, K., 
Soda, M., Ichimaru, S., Nakashima, E., Fujiwara, S., Maeda, R., Nagataki, S., Eguchi, K., 
Akahoshi, M. (2010). Metabolic cardiovascular disease risk factors and their clustering 
in subclinical hypothyroidism. Clin Endocrinol (Oxf), Vol. 72, No. 5 (May 2010), pp. 
689-695, issn  1365-2265 (Electronic) 0300-0664 (Linking). 
Asvold, B.O., Bjoro, T., Nilsen, T.I., Vatten, L.J. (2007). Association between blood pressure 
and serum thyroid-stimulating hormone concentration within the reference range: a 
population-based study. J Clin Endocrinol Metab, Vol. 92, No. 3 (Mar 2007), pp. 841-845, 
issn  0021-972X (Print) 0021-972X (Linking). 
Atzmon, G., Barzilai, N., Hollowell, J.G., Surks, M.I., Gabriely, I. (2009). Extreme longevity is 
associated with increased serum thyrotropin. J Clin Endocrinol Metab, Vol. 94, No. 4 
(Apr 2009), pp. 1251-1254, issn  1945-7197 (Electronic) 0021-972X (Linking). 
Bakker, S.J., ter Maaten, J.C., Popp-Snijders, C., Slaets, J.P., Heine, R.J., Gans, R.O. (2001). The 
relationship between thyrotropin and low density lipoprotein cholesterol is modified by 
insulin sensitivity in healthy euthyroid subjects. J Clin Endocrinol Metab, Vol. 86, No. 3 
(Mar 2001), pp. 1206-1211, issn  0021-972X (Print) 0021-972X (Linking). 
Baloch, Z., Carayon, P., Conte-Devolx, B., Demers, L.M., Feldt-Rasmussen, U., Henry, J.F., 
LiVosli, V.A., Niccoli-Sire, P., John, R., Ruf, J., Smyth, P.P., Spencer, C.A., Stockigt, J.R. 
(2003). Laboratory medicine practice guidelines. Laboratory support for the diagnosis 
and monitoring of thyroid disease. Thyroid, Vol. 13, No. 1 (Jan 2003), pp. 3-126, issn  
1050-7256 (Print) 1050-7256 (Linking). 
Basaria, S., Cooper, D.S. (2005). Amiodarone and the thyroid. Am J Med, Vol. 118, No. 7 (Jul 
2005), pp. 706-714, issn  0002-9343 (Print) 0002-9343 (Linking). 
Belakavadi, M., Dell, J., Grover, G.J., Fondell, J.D. (2011). Thyroid hormone suppression of 
beta-amyloid precursor protein gene expression in the brain involves multiple 
epigenetic regulatory events. Mol Cell Endocrinol, Vol. 339, No. 1-2 (Jun 6 2011), pp. 72-
80, issn  1872-8057 (Electronic) 0303-7207 (Linking). 
 
Thyroid Hormone 200 
Belke, D.D., Gloss, B., Swanson, E.A., Dillmann, W.H. (2007). Adeno-associated virus-
mediated expression of thyroid hormone receptor isoforms-alpha1 and -beta1 improves 
contractile function in pressure overload-induced cardiac hypertrophy. Endocrinology, 
Vol. 148, No. 6 (Jun 2007), pp. 2870-2877, issn  0013-7227 (Print) 0013-7227 (Linking). 
Bemben, D.A., Winn, P., Hamm, R.M., Morgan, L., Davis, A., Barton, E. (1994). Thyroid 
disease in the elderly. Part 1. Prevalence of undiagnosed hypothyroidism. J Fam Pract, 
Vol. 38, No. 6 (Jun 1994), pp. 577-582, issn  0094-3509 (Print) 0094-3509 (Linking). 
Billewicz, W.Z., Chapman, R.S., Crooks, J., Day, M.E., Gossage, J., Wayne, E., Young, J.A. 
(1969). Statistical methods applied to the diagnosis of hypothyroidism. Q J Med, Vol. 38, 
No. 150 (Apr 1969), pp. 255-266, issn  0033-5622 (Print) 0033-5622 (Linking). 
Biondi, B., Cooper, D.S. (2008). The clinical significance of subclinical thyroid dysfunction. 
Endocr Rev, Vol. 29, No. 1 (Feb 2008), pp. 76-131, issn  0163-769X (Print) 0163-769X 
(Linking). 
Biondi B., Cooper, D.S. (2012). Subclinical thyroid disease. Lancet, (Jan 20 2012). [Epub 
ahead of print] PubMed PMID: 22273398. 0140-6736 (Linking) 
Brenta, G., Mutti, L.A., Schnitman, M., Fretes, O., Perrone, A., Matute, M.L. (2003). 
Assessment of left ventricular diastolic function by radionuclide ventriculography at 
rest and exercise in subclinical hypothyroidism, and its response to L-thyroxine 
therapy. Am J Cardiol, Vol. 91, No. 11 (Jun 1 2003), pp. 1327-1330, issn  0002-9149 (Print) 
0002-9149 (Linking). 
Bulens, C. (1981). Neurologic complications of hyperthyroidism: remission of spastic 
paraplegia, dementia, and optic neuropathy. Arch Neurol, Vol. 38, No. 10 (Oct 1981), 
pp. 669-670, issn  0003-9942 (Print) 0003-9942 (Linking). 
Canaris, G.J., Manowitz, N.R., Mayor, G., Ridgway, E.C. (2000). The Colorado thyroid 
disease prevalence study. Arch Intern Med, Vol. 160, No. 4 (Feb 28 2000), pp. 526-534, 
issn  0003-9926 (Print) 0003-9926 (Linking). 
Canaris, G.J., Steiner, J.F., Ridgway, E.C. (1997). Do traditional symptoms of hypothyroidism 
correlate with biochemical disease? J Gen Intern Med, Vol. 12, No. 9 (Sep 1997), pp. 544-
550, issn  0884-8734 (Print) 0884-8734 (Linking). 
Canturk, Z., Cetinarslan, B., Tarkun, I., Canturk, N.Z., Ozden, M. (2003). Lipid profile and 
lipoprotein (a) as a risk factor for cardiovascular disease in women with subclinical 
hypothyroidism. Endocr Res, Vol. 29, No. 3 (Aug 2003), pp. 307-316, issn  0743-5800 
(Print) 0743-5800 (Linking). 
Cappola, A.R., Fried, L.P., Arnold, A.M., Danese, M.D., Kuller, L.H., Burke, G.L., Tracy, R.P., 
Ladenson, P.W. (2006). Thyroid status, cardiovascular risk, and mortality in older 
adults. JAMA, Vol. 295, No. 9 (Mar 1 2006), pp. 1033-1041, issn  1538-3598 (Electronic) 
0098-7484 (Linking). 
Cappola, A.R., Ladenson, P.W. (2003). Hypothyroidism and atherosclerosis. J Clin 
Endocrinol Metab, Vol. 88, No. 6 (Jun 2003), pp. 2438-2444, issn  0021-972X (Print) 0021-
972X (Linking). 
Caraccio, N., Dardano, A., Manfredonia, F., Manca, L., Pasquali, L., Iudice, A., Murri, L., 
Ferrannini, E., Monzani, F. (2005). Long-term follow-up of 106 multiple sclerosis 
patients undergoing interferon-beta 1a or 1b therapy: predictive factors of thyroid 
disease development and duration. J Clin Endocrinol Metab, Vol. 90, No. 7 (Jul 2005), 
pp. 4133-4137, issn  0021-972X (Print) 0021-972X (Linking). 
 
Mild Thyroid Deficiency in the Elderly 201 
Caraccio, N., Ferrannini, E., Monzani, F. (2002). Lipoprotein profile in subclinical 
hypothyroidism: response to levothyroxine replacement, a randomized placebo-
controlled study. J Clin Endocrinol Metab, Vol. 87, No. 4 (Apr 2002), pp. 1533-1538, issn  
0021-972X (Print) 0021-972X (Linking). 
Carle, A., Laurberg, P., Pedersen, I.B., Perrild, H., Ovesen, L., Rasmussen, L.B., Jorgensen, T., 
Knudsen, N. (2007). Age modifies the pituitary TSH response to thyroid failure. 
Thyroid, Vol. 17, No. 2 (Feb 2007), pp. 139-144, issn  1050-7256 (Print) 1050-7256 
(Linking). 
Ceresini, G., Lauretani, F., Maggio, M., Ceda, G.P., Morganti, S., Usberti, E., Chezzi, C., 
Valcavi, R., Bandinelli, S., Guralnik, J.M., Cappola, A.R., Valenti, G., Ferrucci, L. (2009). 
Thyroid function abnormalities and cognitive impairment in elderly people: results of 
the Invecchiare in Chianti study. J Am Geriatr Soc, Vol. 57, No. 1 (Jan 2009), pp. 89-93, 
issn  1532-5415 (Electronic) 0002-8614 (Linking). 
Ceresini, G., Morganti, S., Maggio, M., Usberti, E., Fiorino, I., Artoni, A., Teresi, G., Belli, S., 
Ridolfi, V., Valenti, G., Ceda, G.P. (2010). Subclinical thyroid disease in elderly subjects. 
Acta Biomed, Vol. 81 Suppl 1, No.  2010), pp. 31-36, issn  0392-4203 (Print) 0392-4203 
(Linking). 
Chadarevian, R., Bruckert, E., Leenhardt, L., Giral, P., Ankri, A., Turpin, G. (2001). 
Components of the fibrinolytic system are differently altered in moderate and severe 
hypothyroidism. J Clin Endocrinol Metab, Vol. 86, No. 2 (Feb 2001), pp. 732-737, issn  
0021-972X (Print) 0021-972X (Linking). 
Chait, A., Bierman, E.L., Albers, J.J. (1979). Regulatory role of triiodothyronine in the 
degradation of low density lipoprotein by cultured human skin fibroblasts. J Clin 
Endocrinol Metab, Vol. 48, No. 5 (May 1979), pp. 887-889, issn  0021-972X (Print) 0021-
972X (Linking). 
Chavanne, D., Constans, T., Petit, A., Mondon, K., Hommet, C. (2011). Hypothyroidism and 
cognition in the elderly. Geriatr Psychol Neuropsychiatr Vieil, Vol. 9, No. 4 (Dec 1 
2011), pp. 477-489, issn  2115-8789 (Print) 2115-7863 (Linking). 
Christ-Crain, M., Meier, C., Guglielmetti, M., Huber, P.R., Riesen, W., Staub, J.J., Muller, B. 
(2003). Elevated C-reactive protein and homocysteine values: cardiovascular risk factors 
in hypothyroidism? A cross-sectional and a double-blind, placebo-controlled trial. 
Atherosclerosis, Vol. 166, No. 2 (Feb 2003), pp. 379-386, issn  0021-9150 (Print) 0021-9150 
(Linking). 
Colantuoni, A., Marchiafava, P.L., Lapi, D., Forini, F.S., Iervasi, G. (2005). Effects of 
tetraiodothyronine and triiodothyronine on hamster cheek pouch microcirculation. Am 
J Physiol Heart Circ Physiol, Vol. 288, No. 4 (Apr 2005), pp. H1931-1936, issn  0363-6135 
(Print) 0363-6135 (Linking). 
Cooper, D.S. (2001). Clinical practice. Subclinical hypothyroidism. N Engl J Med, Vol. 345, 
No. 4 (Jul 26 2001), pp. 260-265, issn  0028-4793 (Print) 0028-4793 (Linking). 
Cooper, D.S., Halpern, R., Wood, L.C., Levin, A.A., Ridgway, E.C. (1984). L-Thyroxine 
therapy in subclinical hypothyroidism. A double-blind, placebo-controlled trial. Ann 
Intern Med, Vol. 101, No. 1 (Jul 1984), pp. 18-24, issn  0003-4819 (Print) 0003-4819 
(Linking). 
Correia, N., Mullally, S., Cooke, G., Tun, T.K., Phelan, N., Feeney, J., Fitzgibbon, M., Boran, 
G., O'Mara, S., Gibney, J. (2009). Evidence for a specific defect in hippocampal memory 
 
Thyroid Hormone 202 
in overt and subclinical hypothyroidism. J Clin Endocrinol Metab, Vol. 94, No. 10 (Oct 
2009), pp. 3789-3797, issn  1945-7197 (Electronic) 0021-972X (Linking). 
Corsonello, A., Montesanto, A., Berardelli, M., De Rango, F., Dato, S., Mari, V., Mazzei, B., 
Lattanzio, F., Passarino, G. (2010). A cross-section analysis of FT3 age-related changes in 
a group of old and oldest-old subjects, including centenarians' relatives, shows that a 
down-regulated thyroid function has a familial component and is related to longevity. 
Age Ageing, Vol. 39, No. 6 (Nov 2010), pp. 723-727, issn  1468-2834 (Electronic) 0002-
0729 (Linking). 
Dardano, A.M., Monzani F. (2008). Hypothyroidism and endothelial function: a markers of 
early atherosclerosis? . Recent Patents on Endocrine, Metabolic & Immune Drug 
Discovery, Vol. 2, No. 2 (May 2008 2008), pp. 79-96, issn  1872-2148. 
Davis, J.D., Podolanczuk, A., Donahue, J.E., Stopa, E., Hennessey, J.V., Luo, L.G., Lim, Y.P., 
Stern, R.A. (2008). Thyroid hormone levels in the prefrontal cortex of post-mortem 
brains of Alzheimer's disease patients. Curr Aging Sci, Vol. 1, No. 3 (Dec 2008), pp. 175-
181, issn  1874-6128 (Electronic). 
Dayan, C.M. (2001). Interpretation of thyroid function tests. Lancet, Vol. 357, No. 9256 (Feb 
24 2001), pp. 619-624, issn  0140-6736 (Print) 0140-6736 (Linking). 
Dernellis, J., Panaretou, M. (2002). Effects of thyroid replacement therapy on arterial blood 
pressure in patients with hypertension and hypothyroidism. Am Heart J, Vol. 143, No. 4 
(Apr 2002), pp. 718-724, issn  1097-6744 (Electronic) 0002-8703 (Linking). 
Diez, J.J., Iglesias, P. (2004). Spontaneous subclinical hypothyroidism in patients older than 
55 years: an analysis of natural course and risk factors for the development of overt 
thyroid failure. J Clin Endocrinol Metab, Vol. 89, No. 10 (Oct 2004), pp. 4890-4897, issn  
0021-972X (Print) 0021-972X (Linking). 
Dillmann, W.H. (2002). Cellular action of thyroid hormone on the heart. Thyroid, Vol. 12, 
No. 6 (Jun 2002), pp. 447-452, issn  1050-7256 (Print) 1050-7256 (Linking). 
Duntas, L.H., Mantzou, E., Koutras, D.A. (2002). Circulating levels of oxidized low-density 
lipoprotein in overt and mild hypothyroidism. Thyroid, Vol. 12, No. 11 (Nov 2002), pp. 
1003-1007, issn  1050-7256 (Print) 1050-7256 (Linking). 
Egger, M., Smith, G.D., Sterne, J.A. (2001). Uses and abuses of meta-analysis. Clin Med, Vol. 
1, No. 6 (Nov-Dec 2001), pp. 478-484, issn  1470-2118 (Print) 1470-2118 (Linking). 
Etgen, T., Sander, D., Bickel, H., Forstl, H. (2011). Mild cognitive impairment and dementia: 
the importance of modifiable risk factors. Dtsch Arztebl Int, Vol. 108, No. 44 (Nov 2011), 
pp. 743-750, issn  1866-0452 (Electronic) 1866-0452 (Linking). 
Faber, J., Petersen, L., Wiinberg, N., Schifter, S., Mehlsen, J. (2002). Hemodynamic changes 
after levothyroxine treatment in subclinical hypothyroidism. Thyroid, Vol. 12, No. 4 
(Apr 2002), pp. 319-324, issn  1050-7256 (Print) 1050-7256 (Linking). 
Fatourechi, V. (2009). Subclinical hypothyroidism: an update for primary care physicians. 
Mayo Clin Proc, Vol. 84, No. 1 2009), pp. 65-71, issn  1942-5546 (Electronic) 0025-6196 
(Linking). 
Fommei, E., Iervasi, G. (2002). The role of thyroid hormone in blood pressure homeostasis: 
evidence from short-term hypothyroidism in humans. J Clin Endocrinol Metab, Vol. 87, 
No. 5 (May 2002), pp. 1996-2000, issn  0021-972X (Print) 0021-972X (Linking). 
 
Mild Thyroid Deficiency in the Elderly 203 
Fu, A.L., Zhou, C.Y., Chen, X. (2010). Thyroid hormone prevents cognitive deficit in a mouse 
model of Alzheimer's disease. Neuropharmacology, Vol. 58, No. 4-5 (Mar-Apr 2010), 
pp. 722-729, issn  1873-7064 (Electronic) 0028-3908 (Linking). 
Fukuyama, K., Ichiki, T., Takeda, K., Tokunou, T., Iino, N., Masuda, S., Ishibashi, M., 
Egashira, K., Shimokawa, H., Hirano, K., Kanaide, H., Takeshita, A. (2003). 
Downregulation of vascular angiotensin II type 1 receptor by thyroid hormone. 
Hypertension, Vol. 41, No. 3 (Mar 2003), pp. 598-603, issn  1524-4563 (Electronic) 0194-
911X (Linking). 
Galli, E., Pingitore, A., Iervasi, G. (2010). The role of thyroid hormone in the 
pathophysiology of heart failure: clinical evidence. Heart Fail Rev, Vol. 15, No. 2 (Mar 
2010), pp. 155-169, issn  1573-7322 (Electronic) 1382-4147 (Linking). 
Gardner, D.F. (2004). The neuromuscular system and brain in hypothyroidism,  In: The 
Thyroid, A Fundamental and Clinical Text, Bravermann, L.E., Utiger, R.D. pp. 837841, 
Ninth Edition, Lippincott Williams and Wilkins, ISBN 0-7817-5047-4(HC), Philadelphia, 
USA    
Geul, K.W., van Sluisveld, I.L., Grobbee, D.E., Docter, R., de Bruyn, A.M., Hooykaas, H., van 
der Merwe, J.P., van Hemert, A.M., Krenning, E.P., Hennemann, G., et al. (1993). The 
importance of thyroid microsomal antibodies in the development of elevated serum 
TSH in middle-aged women: associations with serum lipids. Clin Endocrinol (Oxf), Vol. 
39, No. 3 (Sep 1993), pp. 275-280, issn  0300-0664 (Print) 0300-0664 (Linking). 
Gharib, H., Tuttle, R.M., Baskin, H.J., Fish, L.H., Singer, P.A., McDermott, M.T. (2005a). 
Consensus Statement #1: Subclinical thyroid dysfunction: a joint statement on 
management from the American Association of Clinical Endocrinologists, the American 
Thyroid Association, and The Endocrine Society. Thyroid, Vol. 15, No. 1 (Jan 2005a), pp. 
24-28; response 32-23, issn  1050-7256 (Print) 1050-7256 (Linking). 
Gharib, H., Tuttle, R.M., Baskin, H.J., Fish, L.H., Singer, P.A., McDermott, M.T. (2005b). 
Subclinical thyroid dysfunction: a joint statement on management from the American 
Association of Clinical Endocrinologists, the American Thyroid Association, and the 
Endocrine Society. J Clin Endocrinol Metab, Vol. 90, No. 1 (Jan 2005b), pp. 581-585; 
discussion 586-587, issn  0021-972X (Print) 0021-972X (Linking). 
Graham, J.E., Rockwood, K., Beattie, B.L., Eastwood, R., Gauthier, S., Tuokko, H., McDowell, 
I. (1997). Prevalence and severity of cognitive impairment with and without dementia 
in an elderly population. Lancet, Vol. 349, No. 9068 (Jun 21 1997), pp. 1793-1796, issn  
0140-6736 (Print) 0140-6736 (Linking). 
Gussekloo, J., van Exel, E., de Craen, A.J., Meinders, A.E., Frolich, M., Westendorp, R.G. 
(2004). Thyroid status, disability and cognitive function, and survival in old age. JAMA, 
Vol. 292, No. 21 (Dec 1 2004), pp. 2591-2599, issn  1538-3598 (Electronic) 0098-7484 
(Linking). 
Gussekloo, J., van Exel, E., de Craen, A.J., Meinders, A.E., Frolich, M., Westendorp, R.G. 
(2006). [Thyroid function, activities of daily living and survival in extreme old age: the 
'Leiden 85-plus Study']. Ned Tijdschr Geneeskd, Vol. 150, No. 2 (Jan 14 2006), pp. 90-96, 
issn  0028-2162 (Print) 0028-2162 (Linking). 
Hak, A.E., Pols, H.A., Visser, T.J., Drexhage, H.A., Hofman, A., Witteman, J.C. (2000). 
Subclinical hypothyroidism is an independent risk factor for atherosclerosis and 
 
Thyroid Hormone 204 
myocardial infarction in elderly women: the Rotterdam Study. Ann Intern Med, Vol. 
132, No. 4 (Feb 15 2000), pp. 270-278, issn  0003-4819 (Print) 0003-4819 (Linking). 
Hancock, S.L., Cox, R.S., McDougall, I.R. (1991). Thyroid diseases after treatment of 
Hodgkin's disease. N Engl J Med, Vol. 325, No. 9 (Aug 29 1991), pp. 599-605, issn  0028-
4793 (Print) 0028-4793 (Linking). 
Helfand, M. (2004). Screening for subclinical thyroid dysfunction in nonpregnant adults: a 
summary of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med, 
Vol. 140, No. 2 (Jan 20 2004), pp. 128-141, issn  1539-3704 (Electronic) 0003-4819 
(Linking). 
Herholz, K. (2010). Cerebral glucose metabolism in preclinical and prodromal Alzheimer's 
disease. Expert Rev Neurother, Vol. 10, No. 11 (Nov 2010), pp. 1667-1673, issn  1744-
8360 (Electronic) 1473-7175 (Linking). 
Hogervorst, E., Huppert, F., Matthews, F.E., Brayne, C. (2008). Thyroid function and 
cognitive decline in the MRC Cognitive Function and Ageing Study. 
Psychoneuroendocrinology, Vol. 33, No. 7 (Aug 2008), pp. 1013-1022, issn  0306-4530 
(Print) 0306-4530 (Linking). 
Hollowell, J.G., Staehling, N.W., Flanders, W.D., Hannon, W.H., Gunter, E.W., Spencer, 
C.A., Braverman, L.E. (2002). Serum TSH, T(4), and thyroid antibodies in the United 
States population (1988 to 1994): National Health and Nutrition Examination Survey 
(NHANES III). J Clin Endocrinol Metab, Vol. 87, No. 2 (Feb 2002), pp. 489-499, issn  
0021-972X (Print) 0021-972X (Linking). 
Imaizumi, M., Akahoshi, M., Ichimaru, S., Nakashima, E., Hida, A., Soda, M., Usa, T., 
Ashizawa, K., Yokoyama, N., Maeda, R., Nagataki, S., Eguchi, K. (2004). Risk for 
ischemic heart disease and all-cause mortality in subclinical hypothyroidism. J Clin 
Endocrinol Metab, Vol. 89, No. 7 (Jul 2004), pp. 3365-3370, issn  0021-972X (Print) 0021-
972X (Linking). 
Jaeschke, R., Guyatt, G., Gerstein, H., Patterson, C., Molloy, W., Cook, D., Harper, S., 
Griffith, L., Carbotte, R. (1996). Does treatment with L-thyroxine influence health status 
in middle-aged and older adults with subclinical hypothyroidism? J Gen Intern Med, 
Vol. 11, No. 12 (Dec 1996), pp. 744-749, issn  0884-8734 (Print) 0884-8734 (Linking). 
Kahaly, G.J. (2000). Cardiovascular and atherogenic aspects of subclinical hypothyroidism. 
Thyroid, Vol. 10, No. 8 (Aug 2000), pp. 665-679, issn  1050-7256 (Print) 1050-7256 
(Linking). 
Kahaly, G.J., Dillmann, W.H. (2005). Thyroid hormone action in the heart. Endocr Rev, Vol. 
26, No. 5 (Aug 2005), pp. 704-728, issn  0163-769X (Print) 0163-769X (Linking). 
Kalmijn, S., Foley, D., White, L., Burchfiel, C.M., Curb, J.D., Petrovitch, H., Ross, G.W., 
Havlik, R.J., Launer, L.J. (2000). Metabolic cardiovascular syndrome and risk of 
dementia in Japanese-American elderly men. The Honolulu-Asia aging study. 
Arterioscler Thromb Vasc Biol, Vol. 20, No. 10 (Oct 2000), pp. 2255-2260, issn  1524-4636 
(Electronic) 1079-5642 (Linking). 
Kanaya, A.M., Harris, F., Volpato, S., Perez-Stable, E.J., Harris, T., Bauer, D.C. (2002). 
Association between thyroid dysfunction and total cholesterol level in an older biracial 
population: the health, aging and body composition study. Arch Intern Med, Vol. 162, 
No. 7 (Apr 8 2002), pp. 773-779, issn  0003-9926 (Print) 0003-9926 (Linking). 
 
Mild Thyroid Deficiency in the Elderly 205 
Karmisholt, J., Andersen, S., Laurberg, P. (2011). Variation in thyroid function in subclinical 
hypothyroidism: importance of clinical follow-up and therapy. Eur J Endocrinol, Vol. 
164, No. 3 (Mar 2011), pp. 317-323, issn  1479-683X (Electronic) 0804-4643 (Linking). 
Klein, I. (2004). The cardiovascular system in hypothyroidism, In: The Thyroid, A 
Fundamental and Clinical Text, Bravermann, L.E., Utiger, R.D. pp. 774-80, Ninth 
Edition, Lippincott Williams and Wilkins, ISBN 0-7817-5047-4(HC), Philadelphia, USA    
Klein, I., Danzi, S. (2007). Thyroid disease and the heart. Circulation, Vol. 116, No. 15 (Oct 9 
2007), pp. 1725-1735, issn  1524-4539 (Electronic) 0009-7322 (Linking). 
Klein, I., Ojamaa, K. (2001). Thyroid hormone and the cardiovascular system. N Engl J Med, 
Vol. 344, No. 7 (Feb 15 2001), pp. 501-509, issn  0028-4793 (Print) 0028-4793 (Linking). 
Kong, W.M., Sheikh, M.H., Lumb, P.J., Naoumova, R.P., Freedman, D.B., Crook, M., Dore, 
C.J., Finer, N. (2002). A 6-month randomized trial of thyroxine treatment in women 
with mild subclinical hypothyroidism. Am J Med, Vol. 112, No. 5 (Apr 1 2002), pp. 348-
354, issn  0002-9343 (Print) 0002-9343 (Linking). 
Kumar, N., Allen, K.A., Riccardi, D., Bercu, B.B., Cantor, A., Minton, S., Balducci, L., 
Jacobsen, P.B. (2004). Fatigue, weight gain, lethargy and amenorrhea in breast cancer 
patients on chemotherapy: is subclinical hypothyroidism the culprit? Breast Cancer Res 
Treat, Vol. 83, No. 2 (Jan 2004), pp. 149-159, issn  0167-6806 (Print) 0167-6806 (Linking). 
Kvetny, J., Heldgaard, P.E., Bladbjerg, E.M., Gram, J. (2004). Subclinical hypothyroidism is 
associated with a low-grade inflammation, increased triglyceride levels and predicts 
cardiovascular disease in males below 50 years. Clin Endocrinol (Oxf), Vol. 61, No. 2 
(Aug 2004), pp. 232-238, issn  0300-0664 (Print) 0300-0664 (Linking). 
Ladenson, P.W., Singer, P.A., Ain, K.B., Bagchi, N., Bigos, S.T., Levy, E.G., Smith, S.A., 
Daniels, G.H., Cohen, H.D. (2000). American Thyroid Association guidelines for 
detection of thyroid dysfunction. Arch Intern Med, Vol. 160, No. 11 (Jun 12 2000), pp. 
1573-1575, issn  0003-9926 (Print) 0003-9926 (Linking). 
Laurberg, P., Andersen, S., Carle, A., Karmisholt, J., Knudsen, N., Pedersen, I.B. (2011). The 
TSH upper reference limit: where are we at? Nat Rev Endocrinol, Vol. 7, No. 4 (Apr 
2011), pp. 232-239, issn  1759-5037 (Electronic) 1759-5029 (Linking). 
Lee, W.Y., Suh, J.Y., Rhee, E.J., Park, J.S., Sung, K.C., Kim, S.W. (2004). Plasma CRP, 
apolipoprotein A-1, apolipoprotein B and Lpa levels according to thyroid function 
status. Arch Med Res, Vol. 35, No. 6 (Nov-Dec 2004), pp. 540-545, issn  0188-4409 (Print) 
0188-4409 (Linking). 
Lekakis, J., Papamichael, C., Alevizaki, M., Piperingos, G., Marafelia, P., Mantzos, J., 
Stamatelopoulos, S., Koutras, D.A. (1997). Flow-mediated, endothelium-dependent 
vasodilation is impaired in subjects with hypothyroidism, borderline hypothyroidism, 
and high-normal serum thyrotropin (TSH) values. Thyroid, Vol. 7, No. 3 (Jun 1997), pp. 
411-414, issn  1050-7256 (Print) 1050-7256 (Linking). 
Luboshitzky, R., Aviv, A., Herer, P., Lavie, L. (2002). Risk factors for cardiovascular disease 
in women with subclinical hypothyroidism. Thyroid, Vol. 12, No. 5 (May 2002), pp. 421-
425, issn  1050-7256 (Print) 1050-7256 (Linking). 
Luboshitzky, R., Herer, P. (2004). Cardiovascular risk factors in middle-aged women with 
subclinical hypothyroidism. Neuro Endocrinol Lett, Vol. 25, No. 4 (Aug 2004), pp. 262-
266, issn  0172-780X (Print) 0172-780X (Linking). 
 
Thyroid Hormone 206 
Mariotti, S. (2005). Thyroid function and aging: do serum 3,5,3'-triiodothyronine and 
thyroid-stimulating hormone concentrations give the Janus response? J Clin Endocrinol 
Metab, Vol. 90, No. 12 (Dec 2005), pp. 6735-6737, issn  0021-972X (Print) 0021-972X 
(Linking). 
Mariotti, S., Barbesino, G., Caturegli, P., Bartalena, L., Sansoni, P., Fagnoni, F., Monti, D., 
Fagiolo, U., Franceschi, C., Pinchera, A. (1993). Complex alteration of thyroid function 
in healthy centenarians. J Clin Endocrinol Metab, Vol. 77, No. 5 (Nov 1993), pp. 1130-
1134, issn  0021-972X (Print) 0021-972X (Linking). 
Mariotti, S., Franceschi, C., Cossarizza, A., Pinchera, A. (1995). The aging thyroid. Endocr 
Rev, Vol. 16, No. 6 (Dec 1995), pp. 686-715, issn  0163-769X (Print) 0163-769X (Linking). 
Meier, C., Staub, J.J., Roth, C.B., Guglielmetti, M., Kunz, M., Miserez, A.R., Drewe, J., Huber, 
P., Herzog, R., Muller, B. (2001). TSH-controlled L-thyroxine therapy reduces 
cholesterol levels and clinical symptoms in subclinical hypothyroidism: a double blind, 
placebo-controlled trial (Basel Thyroid Study). J Clin Endocrinol Metab, Vol. 86, No. 10 
(Oct 2001), pp. 4860-4866, issn  0021-972X (Print) 0021-972X (Linking). 
Mitrou, P., Raptis, S.A., Dimitriadis, G. (2011). Thyroid disease in older people. Maturitas, 
Vol., No.  (Jun 28 2011), pp.  issn  1873-4111 (Electronic) 0378-5122 (Linking). 
Mohandas, R., Gupta, K.L. (2003). Managing thyroid dysfunction in the elderly. Answers to 
seven common questions. Postgrad Med, Vol. 113, No. 5 (May 2003), pp. 54-56, 65-58, 
100, issn  0032-5481 (Print) 0032-5481 (Linking). 
Monzani, F., Caraccio, N., Kozakowa, M., Dardano, A., Vittone, F., Virdis, A., Taddei, S., 
Palombo, C., Ferrannini, E. (2004). Effect of levothyroxine replacement on lipid profile 
and intima-media thickness in subclinical hypothyroidism: a double-blind, placebo- 
controlled study. J Clin Endocrinol Metab, Vol. 89, No. 5 (May 2004), pp. 2099-2106, issn  
0021-972X (Print) 0021-972X (Linking). 
Monzani, F., Dardano, A., Caraccio, N. (2006). Does treating subclinical hypothyroidism 
improve markers of cardiovascular risk? Treat Endocrinol, Vol. 5, No. 2 2006), pp. 65-81, 
issn  1175-6349 (Print) 1175-6349 (Linking). 
Monzani, F., Del Guerra, P., Caraccio, N., Pruneti, C.A., Pucci, E., Luisi, M., Baschieri, L. 
(1993). Subclinical hypothyroidism: neurobehavioral features and beneficial effect of L-
thyroxine treatment. Clin Investig, Vol. 71, No. 5 (May 1993), pp. 367-371, issn  0941-
0198 (Print) 0941-0198 (Linking). 
Muller, B., Tsakiris, D.A., Roth, C.B., Guglielmetti, M., Staub, J.J., Marbet, G.A. (2001). 
Haemostatic profile in hypothyroidism as potential risk factor for vascular or 
thrombotic disease. Eur J Clin Invest, Vol. 31, No. 2 (Feb 2001), pp. 131-137, issn  0014-
2972 (Print) 0014-2972 (Linking). 
Nystrom, E., Caidahl, K., Fager, G., Wikkelso, C., Lundberg, P.A., Lindstedt, G. (1988). A 
double-blind cross-over 12-month study of L-thyroxine treatment of women with 
'subclinical' hypothyroidism. Clin Endocrinol (Oxf), Vol. 29, No. 1 (Jul 1988), pp. 63-75, 
issn  0300-0664 (Print) 0300-0664 (Linking). 
Ochs, N., Auer, R., Bauer, D.C., Nanchen, D., Gussekloo, J., Cornuz, J., Rodondi, N. (2008). 
Meta-analysis: subclinical thyroid dysfunction and the risk for coronary heart disease 
and mortality. Ann Intern Med, Vol. 148, No. 11 (Jun 3 2008), pp. 832-845, issn  1539-
3704 (Electronic) 0003-4819 (Linking). 
 
Mild Thyroid Deficiency in the Elderly 207 
Ojamaa, K., Klemperer, J.D., Klein, I. (1996). Acute effects of thyroid hormone on vascular 
smooth muscle. Thyroid, Vol. 6, No. 5 (Oct 1996), pp. 505-512, issn  1050-7256 (Print) 
1050-7256 (Linking). 
Olsen, K.J. (1978). Scintigraphic estimation of thyroid volume and dose distribution at 
treatment with 131I. Acta Radiol Oncol Radiat Phys Biol, Vol. 17, No. 1 1978), pp. 74-80, 
issn  0348-5196 (Print) 0348-5196 (Linking). 
Ooka, H., Fujita, S., Yoshimoto, E. (1983). Pituitary-thyroid activity and longevity in 
neonatally thyroxine-treated rats. Mech Ageing Dev, Vol. 22, No. 2 (Jun 1983), pp. 113-
120, issn  0047-6374 (Print) 0047-6374 (Linking). 
Osterweil, D., Syndulko, K., Cohen, S.N., Pettler-Jennings, P.D., Hershman, J.M., Cummings, 
J.L., Tourtellotte, W.W., Solomon, D.H. (1992). Cognitive function in non-demented 
older adults with hypothyroidism. J Am Geriatr Soc, Vol. 40, No. 4 (Apr 1992), pp. 325-
335, issn  0002-8614 (Print) 0002-8614 (Linking). 
Palmieri, E.A., Fazio, S., Lombardi, G., Biondi, B. (2004). Subclinical hypothyroidism and 
cardiovascular risk: a reason to treat? Treat Endocrinol, Vol. 3, No. 4 2004), pp. 233-244, 
issn  1175-6349 (Print) 1175-6349 (Linking). 
Patel, J., Landers, K., Li, H., Mortimer, R.H., Richard, K. (2011). Thyroid hormones and fetal 
neurological development. J Endocrinol, Vol. 209, No. 1 (Apr 2011), pp. 1-8, issn  1479-
6805 (Electronic) 0022-0795 (Linking). 
Prinz, P.N., Scanlan, J.M., Vitaliano, P.P., Moe, K.E., Borson, S., Toivola, B., Merriam, G.R., 
Larsen, L.H., Reed, H.L. (1999). Thyroid hormones: positive relationships with 
cognition in healthy, euthyroid older men. J Gerontol A Biol Sci Med Sci, Vol. 54, No. 3 
(Mar 1999), pp. M111-116, issn  1079-5006 (Print) 1079-5006 (Linking). 
Razvi, S., Ingoe, L., Keeka, G., Oates, C., McMillan, C., Weaver, J.U. (2007). The beneficial 
effect of L-thyroxine on cardiovascular risk factors, endothelial function, and quality of 
life in subclinical hypothyroidism: randomized, crossover trial. J Clin Endocrinol 
Metab, Vol. 92, No. 5 (May 2007), pp. 1715-1723, issn  0021-972X (Print) 0021-972X 
(Linking). 
Razvi, S., Shakoor, A., Vanderpump, M., Weaver, J.U., Pearce, S.H. (2008). The influence of 
age on the relationship between subclinical hypothyroidism and ischemic heart disease: 
a metaanalysis. J Clin Endocrinol Metab, Vol. 93, No. 8 (Aug 2008), pp. 2998-3007, issn  
0021-972X (Print) 0021-972X (Linking). 
Razvi, S., Weaver, J.U., Vanderpump, M.P., Pearce, S.H. (2010). The incidence of ischemic 
heart disease and mortality in people with subclinical hypothyroidism: reanalysis of the 
Whickham Survey cohort. J Clin Endocrinol Metab, Vol. 95, No. 4 (Apr 2010), pp. 1734-
1740, issn  1945-7197 (Electronic) 0021-972X (Linking). 
Rivolta, G., Cerutti, R., Colombo, R., Miano, G., Dionisio, P., Grossi, E. (1999). Prevalence of 
subclinical hypothyroidism in a population living in the Milan metropolitan area. J 
Endocrinol Invest, Vol. 22, No. 9 (Oct 1999), pp. 693-697, issn  0391-4097 (Print) 0391-
4097 (Linking). 
Roberts, L.M., Pattison, H., Roalfe, A., Franklyn, J., Wilson, S., Hobbs, F.D., Parle, J.V. (2006). 
Is subclinical thyroid dysfunction in the elderly associated with depression or cognitive 
dysfunction? Ann Intern Med, Vol. 145, No. 8 (Oct 17 2006), pp. 573-581, issn  1539-3704 
(Electronic) 0003-4819 (Linking). 
 
Thyroid Hormone 208 
Rodondi, N., Aujesky, D., Vittinghoff, E., Cornuz, J., Bauer, D.C. (2006). Subclinical 
hypothyroidism and the risk of coronary heart disease: a meta-analysis. Am J Med, Vol. 
119, No. 7 (Jul 2006), pp. 541-551, issn  1555-7162 (Electronic) 0002-9343 (Linking). 
Rodondi, N., den Elzen, W.P., Bauer, D.C., Cappola, A.R., Razvi, S., Walsh, J.P., Asvold, 
B.O., Iervasi, G., Imaizumi, M., Collet, T.H., Bremner, A., Maisonneuve, P., Sgarbi, J.A., 
Khaw, K.T., Vanderpump, M.P., Newman, A.B., Cornuz, J., Franklyn, J.A., Westendorp, 
R.G., Vittinghoff, E., Gussekloo, J. (2010). Subclinical hypothyroidism and the risk of 
coronary heart disease and mortality. JAMA, Vol. 304, No. 12 (Sep 22 2010), pp. 1365-
1374, issn  1538-3598 (Electronic) 0098-7484 (Linking). 
Ross, D.S., (2004). subclinical hypothyroidism, in: The thyroid, A Fundamental and  Clinical 
Text. Lippincott Williams and Wilkins, isbn 0-7817-5047-4 (HC),  Philadelphia. 
Rozing, M.P., Houwing-Duistermaat, J.J., Slagboom, P.E., Beekman, M., Frolich, M., de 
Craen, A.J., Westendorp, R.G., van Heemst, D. (2010). Familial longevity is associated 
with decreased thyroid function. J Clin Endocrinol Metab, Vol. 95, No. 11 (Nov 2010), 
pp. 4979-4984, issn  1945-7197 (Electronic) 0021-972X (Linking). 
Samuels, M.H. (1998). Subclinical thyroid disease in the elderly. Thyroid, Vol. 8, No. 9 (Sep 
1998), pp. 803-813, issn  1050-7256 (Print) 1050-7256 (Linking). 
Sawin, C.T., Castelli, W.P., Hershman, J.M., McNamara, P., Bacharach, P. (1985). The aging 
thyroid. Thyroid deficiency in the Framingham Study. Arch Intern Med, Vol. 145, No. 8 
(Aug 1985), pp. 1386-1388, issn  0003-9926 (Print) 0003-9926 (Linking). 
Sawin, C.T., Chopra, D., Azizi, F., Mannix, J.E., Bacharach, P. (1979). The aging thyroid. 
Increased prevalence of elevated serum thyrotropin levels in the elderly. JAMA, Vol. 
242, No. 3 (Jul 20 1979), pp. 247-250, issn  0098-7484 (Print) 0098-7484 (Linking). 
Shih, C.H., Chen, S.L., Yen, C.C., Huang, Y.H., Chen, C.D., Lee, Y.S., Lin, K.H. (2004). 
Thyroid hormone receptor-dependent transcriptional regulation of fibrinogen and 
coagulation proteins. Endocrinology, Vol. 145, No. 6 (Jun 2004), pp. 2804-2814, issn  
0013-7227 (Print) 0013-7227 (Linking). 
Singh, S., Duggal, J., Molnar, J., Maldonado, F., Barsano, C.P., Arora, R. (2008). Impact of 
subclinical thyroid disorders on coronary heart disease, cardiovascular and all-cause 
mortality: a meta-analysis. Int J Cardiol, Vol. 125, No. 1 (Mar 28 2008), pp. 41-48, issn  
1874-1754 (Electronic) 0167-5273 (Linking). 
Spencer, C.A., Schwarzbein, D., Guttler, R.B., LoPresti, J.S., Nicoloff, J.T. (1993). Thyrotropin 
(TSH)-releasing hormone stimulation test responses employing third and fourth 
generation TSH assays. J Clin Endocrinol Metab, Vol. 76, No. 2 (Feb 1993), pp. 494-498, 
issn  0021-972X (Print) 0021-972X (Linking). 
Squizzato, A., Romualdi, E., Piantanida, E., Gerdes, V.E., Buller, H.R., Tanda, M., Bartalena, 
L., Venco, A., Ageno, W. (2007). Subclinical hypothyroidism and deep venous 
thrombosis. A pilot cross-sectional study. Thromb Haemost, Vol. 97, No. 5 (May 2007), 
pp. 803-806, issn  0340-6245 (Print) 0340-6245 (Linking). 
St John, J.A., Henderson, V.W., Gatto, N.M., McCleary, C.A., Spencer, C.A., Hodis, H.N., 
Mack, W.J. (2009). Mildly elevated TSH and cognition in middle-aged and older adults. 
Thyroid, Vol. 19, No. 2 (Feb 2009), pp. 111-117, issn  1557-9077 (Electronic) 1050-7256 
(Linking). 
Staub, J.J., Althaus, B.U., Engler, H., Ryff, A.S., Trabucco, P., Marquardt, K., Burckhardt, D., 
Girard, J., Weintraub, B.D. (1992). Spectrum of subclinical and overt hypothyroidism: 
 
Mild Thyroid Deficiency in the Elderly 209 
effect on thyrotropin, prolactin, and thyroid reserve, and metabolic impact on 
peripheral target tissues. Am J Med, Vol. 92, No. 6 (Jun 1992), pp. 631-642, issn  0002-
9343 (Print) 0002-9343 (Linking). 
Surks, M.I., Hollowell, J.G. (2007). Age-specific distribution of serum thyrotropin and 
antithyroid antibodies in the US population: implications for the prevalence of 
subclinical hypothyroidism. J Clin Endocrinol Metab, Vol. 92, No. 12 (Dec 2007), pp. 
4575-4582, issn  0021-972X (Print) 0021-972X (Linking). 
Surks, M.I., Ocampo, E. (1996). Subclinical thyroid disease. Am J Med, Vol. 100, No. 2 (Feb 
1996), pp. 217-223, issn  0002-9343 (Print) 0002-9343 (Linking). 
Surks, M.I., Ortiz, E., Daniels, G.H., Sawin, C.T., Col, N.F., Cobin, R.H., Franklyn, J.A., 
Hershman, J.M., Burman, K.D., Denke, M.A., Gorman, C., Cooper, R.S., Weissman, N.J. 
(2004). Subclinical thyroid disease: scientific review and guidelines for diagnosis and 
management. JAMA, Vol. 291, No. 2 (Jan 14 2004), pp. 228-238, issn  1538-3598 
(Electronic) 0098-7484 (Linking). 
Szabolcs, I., Podoba, J., Feldkamp, J., Dohan, O., Farkas, I., Sajgo, M., Takats, K.I., Goth, M., 
Kovacs, L., Kressinszky, K., Hnilica, P., Szilagyi, G. (1997). Comparative screening for 
thyroid disorders in old age in areas of iodine deficiency, long-term iodine prophylaxis 
and abundant iodine intake. Clin Endocrinol (Oxf), Vol. 47, No. 1 (Jul 1997), pp. 87-92, 
issn  0300-0664 (Print) 0300-0664 (Linking). 
Taddei, S., Caraccio, N., Virdis, A., Dardano, A., Versari, D., Ghiadoni, L., Ferrannini, E., 
Salvetti, A., Monzani, F. (2006). Low-grade systemic inflammation causes endothelial 
dysfunction in patients with Hashimoto's thyroiditis. J Clin Endocrinol Metab, Vol. 91, 
No. 12 (Dec 2006), pp. 5076-5082, issn  0021-972X (Print) 0021-972X (Linking). 
Taddei, S., Caraccio, N., Virdis, A., Dardano, A., Versari, D., Ghiadoni, L., Salvetti, A., 
Ferrannini, E., Monzani, F. (2003). Impaired endothelium-dependent vasodilatation in 
subclinical hypothyroidism: beneficial effect of levothyroxine therapy. J Clin Endocrinol 
Metab, Vol. 88, No. 8 (Aug 2003), pp. 3731-3737, issn  0021-972X (Print) 0021-972X 
(Linking). 
Tan, Z.S., Beiser, A., Vasan, R.S., Au, R., Auerbach, S., Kiel, D.P., Wolf, P.A., Seshadri, S. 
(2008). Thyroid function and the risk of Alzheimer disease: the Framingham Study. 
Arch Intern Med, Vol. 168, No. 14 (Jul 28 2008), pp. 1514-1520, issn  1538-3679 
(Electronic) 0003-9926 (Linking). 
Tappy, L., Randin, J.P., Schwed, P., Wertheimer, J., Lemarchand-Beraud, T. (1987). 
Prevalence of thyroid disorders in psychogeriatric inpatients. A possible relationship of 
hypothyroidism with neurotic depression but not with dementia. J Am Geriatr Soc, Vol. 
35, No. 6 (Jun 1987), pp. 526-531, issn  0002-8614 (Print) 0002-8614 (Linking). 
Tunbridge, W.M., Evered, D.C., Hall, R., Appleton, D., Brewis, M., Clark, F., Evans, J.G., 
Young, E., Bird, T., Smith, P.A. (1977). The spectrum of thyroid disease in a community: 
the Whickham survey. Clin Endocrinol (Oxf), Vol. 7, No. 6 (Dec 1977), pp. 481-493, issn  
0300-0664 (Print) 0300-0664 (Linking). 
Turemen, E.E., Cetinarslan, B., Sahin, T., Canturk, Z., Tarkun, I. (2011). Endothelial 
dysfunction and low grade chronic inflammation in subclinical hypothyroidism due to 
autoimmune thyroiditis. Endocr J, Vol. 58, No. 5 2011), pp. 349-354, issn  1348-4540 
(Electronic) 0918-8959 (Linking). 
 
Thyroid Hormone 210 
van den Beld, A.W., Visser, T.J., Feelders, R.A., Grobbee, D.E., Lamberts, S.W. (2005). 
Thyroid hormone concentrations, disease, physical function, and mortality in elderly 
men. J Clin Endocrinol Metab, Vol. 90, No. 12 (Dec 2005), pp. 6403-6409, issn  0021-972X 
(Print) 0021-972X (Linking). 
Vanderpump, M.P., Tunbridge, W.M., French, J.M., Appleton, D., Bates, D., Clark, F., 
Grimley Evans, J., Hasan, D.M., Rodgers, H., Tunbridge, F., et al. (1995). The incidence 
of thyroid disorders in the community: a twenty-year follow-up of the Whickham 
Survey. Clin Endocrinol (Oxf), Vol. 43, No. 1 (Jul 1995), pp. 55-68, issn  0300-0664 (Print) 
0300-0664 (Linking). 
Villar, H.C., Saconato, H., Valente, O., Atallah, A.N. (2007). Thyroid hormone replacement 
for subclinical hypothyroidism. Cochrane Database Syst Rev, Vol., No. 3 2007), pp. 
CD003419, issn  1469-493X (Electronic) 1361-6137 (Linking). 
Volpato, S., Guralnik, J.M., Fried, L.P., Remaley, A.T., Cappola, A.R., Launer, L.J. (2002). 
Serum thyroxine level and cognitive decline in euthyroid older women. Neurology, 
Vol. 58, No. 7 (Apr 9 2002), pp. 1055-1061, issn  0028-3878 (Print) 0028-3878 (Linking). 
Walsh, J.P., Bremner, A.P., Bulsara, M.K., O'Leary, P., Leedman, P.J., Feddema, P., 
Michelangeli, V. (2005). Thyroid dysfunction and serum lipids: a community-based 
study. Clin Endocrinol (Oxf), Vol. 63, No. 6 (Dec 2005), pp. 670-675, issn  0300-0664 
(Print) 0300-0664 (Linking). 
Walton, K.W., Campbell, D.A., Tonks, E.L. (1965). The significance of alterations in serum 
lipids in thyroid dysfunction. I. The relation between serum lipoproteins, carotenoids 
and vitamin A in hypothyroidism and thyrotoxicosis. Clin Sci, Vol. 29, No. 2 (Oct 1965), 
pp. 199-215, issn  0009-9287 (Print) 0009-9287 (Linking). 
Wang, C., Crapo, L.M. (1997). The epidemiology of thyroid disease and implications for 
screening. Endocrinol Metab Clin North Am, Vol. 26, No. 1 (Mar 1997), pp. 189-218, issn  
0889-8529 (Print) 0889-8529 (Linking). 
Yamamoto, N., Ishizawa, K., Ishikawa, M., Yamanaka, G., Yamanaka, T., Murakami, S., 
Hiraiwa, T., Okumiya, K., Ishine, M., Matsubayashi, K., Otsuka, K. (2012). Cognitive 
function with subclinical hypothyroidism in elderly people without dementia: One year 
follow up. Geriatr Gerontol Int, Vol. 12, No. 1 (Jan 2012), pp. 164-165, issn  1447-0594 
(Electronic) 1447-0594 (Linking). 
Zoeller, R.T., Rovet, J. (2004). Timing of thyroid hormone action in the developing brain: 
clinical observations and experimental findings. J Neuroendocrinol, Vol. 16, No. 10 (Oct 
2004), pp. 809-818, issn  0953-8194 (Print) 0953-8194 (Linking). 
Zulewski, H., Muller, B., Exer, P., Miserez, A.R., Staub, J.J. (1997). Estimation of tissue 
hypothyroidism by a new clinical score: evaluation of patients with various grades of 
hypothyroidism and controls. J Clin Endocrinol Metab, Vol. 82, No. 3 (Mar 1997), pp. 
771-776, issn  0021-972X (Print) 0021-972X (Linking). 
